

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

International Mixed Methods Study Protocol to Develop a Patient-Reported Outcome Measure for all Types of Chronic Wounds (the WOUND-Q)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032332
Article Type:	Protocol
Date Submitted by the Author:	03-Jul-2019
Complete List of Authors:	Klassen, Anne; McMaster University, Pediatrics van Haren, Emiel; Catharina Ziekenhuis, Plastic and Reconstructive Surgery, Cross, Karen; St Michael's Hospital, Plastic Surgery Gibbons, Chris; Harvard Medical School, Faculty of Medicine Hoogbergen, Maarten; Catharina Ziekenhuis Longmire, Natasha; McMaster University Poulsen, Lotte; University of Southern Denmark Sorensen, Jens; Odense University Hospital Squirtieri, Lee; University of Southern California, Surgery Tsangaris, Elena; Brigham and Women's Hospital van Alphen, Tert; Catharina Ziekenhuis van Dishoeck, Anne-Margreet; Erasmus Medical Center, Plastic Surgery Vasilic, Dali; Erasmus Medical Center, Plastic Surgery Pusic, Andrea; Brigham and Women's Hospital Biomedical Research Institute
Keywords:	patient-reported outcome, quality of life, psychometrics, Rasch, WOUND MANAGEMENT, PLASTIC & RECONSTRUCTIVE SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title:** International Mixed Methods Study Protocol to Develop a Patient-Reported Outcome Measure for
4 all Types of Chronic Wounds (the WOUND-Q)
5
6
7

8
9 **Authors:**
10

- 11
12 1. Anne F. Klassen DPhil, Department of Pediatrics, McMaster University, 3N27, 1280 Main Street W,
13
14 Hamilton, ON, Canada
- 15
16 2. Emiel LWG van Haren MD, Department of Plastic and Reconstructive Surgery, Catharina
17
18 Ziekenhuis, Eindhoven, the Netherlands
- 19
20 3. Karen Cross MD PhD, Department of Plastic Surgery, St. Michael's Hospital and Keenan Research
21
22 Centre, Toronto, Ontario, Canada
- 23
24 4. Chris Gibbons PhD, Department of Surgery, Brigham and Women's Hospital, 75 Francis S, Boston,
25
26 MA, USA
- 27
28 5. Maarten M Hoogbergen MD PhD, Department of Plastic and Reconstructive Surgery, Catharina
29
30 Ziekenhuis, Eindhoven, the Netherlands
- 31
32 6. Natasha Longmire MSc, Department of Psychology, University of Toronto, Toronto, ON, Canada
- 33
34 7. Lotte Poulsen MD, Department of Plastic and Reconstructive Surgery, University of Southern
35
36 Denmark, Odense, Denmark
- 37
38 8. Jens Ahm Sørensen MD PhD, Department of Plastic and Reconstructive Surgery, Odense University
39
40 Hospital, Odense, Denmark
- 41
42 9. Lee Squitieri MD, PhD, MS, Division of Plastic and Reconstructive Surgery, University of Southern
43
44 California, Los Angeles, CA, USA
- 45
46 10. Elena Tsangaris PhD, Department of Surgery, Brigham and Women's Hospital, 75 Francis St,
47
48 Boston, MA, USA
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 11. Tert C van Alphen MD, Department of Plastic and Reconstructive Surgery, Catharina Ziekenhuis,
4
5 Eindhoven, The Netherlands
6

7
8 12. Andrea L Pusic MD MSc, Department of Surgery, Brigham and Women's Hospital, 75 Francis S,
9
10 Boston, MA, USA
11

12
13 **Corresponding Author:** Andrea Pusic MD MSc, Department of Surgery Brigham and Women's
14
15 Hospital, 75 Francis S, Boston, MA, USA, 02116, apusic@bwh.harvard.edu
16
17

18
19 **Funding Statement:** Phases I and II of this study are funded by research grants received from the
20
21 Plastic Surgery Foundation (120593). The authors have no financial interest to declare in relation to the
22
23 content of this article. The Article Processing Charge was paid from the Plastic Surgery Foundation
24
25 grant.
26
27

28
29 **Contributions:** AFK, ALP conceived and designed the study. AFK, ELWGvH, KC, CG, MMH, NL,
30
31 LP, JS, LS, ET, TCvA, ALP revised the article critically for important intellectual content and have
32
33 approved the final version to be published.
34
35
36

37
38 **Competing Interests Statement:** The authors have no competing interests to report.
39
40

41 **Word count = (maximum 4000)**
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT = 270 of 300

Introduction: Most patient-reported outcome measures (PROM) for chronic wounds are specific to a single wound type (e.g., pressure ulcer) or part of the body. A barrier to outcome assessment in wound care and research is the lack of a rigorously-designed PROM that can be used across wound types and locations. This mixed method study describes the protocol for an international collaboration to develop and validate a new PROM called the WOUND-Q.

Methods and analysis: In phase 1, the qualitative approach of interpretive description is used to elicit concepts important to people with wounds regarding outcome. Participants from Canada, Denmark, the Netherlands, and the USA are aged 18 years and older and have a wound that has lasted 3 months or longer. Interviews are digitally recorded, transcribed and coded. A conceptual framework and preliminary item pool are developed from the qualitative dataset. Draft scales are formed to cover important themes in the conceptual framework. These scales are refined using feedback from people with chronic wounds and wound care experts. After refinement, the scales are translated into Danish and Dutch following rigorous methods to prepare for the international field-test study. In phase II, data are collected in Canada, Denmark, the Netherlands, and the USA. An international sample of people with a large variety of chronic wounds complete the WOUND-Q. Rasch Measurement Theory analysis is used to identify the best subset of items to retain for each scale and to examine reliability and validity.

Ethics and dissemination: This study is coordinated at Brigham and Women's Hospital (Boston, USA). Ethics board approval was received at each participating site for both study phases. Findings will be published in peer-reviewed journals and presented at national and international conferences and meetings.

Strengths and limitations of this study

- Recruitment of an international sample makes it possible to develop an internationally-applicable patient-reported outcome measure (PROM).
- Including people with varying types of chronic wounds in different locations on the body ensures that the WOUND-Q is broadly applicable.
- We adhere to published guidelines for PROM development, including rigorous methods for translation and cultural adaptation.
- We use a modern psychometric approach (Rasch Measurement Theory) to enhance the interpretability of WOUND-Q scores.

INTRODUCTION

Each year, millions of individuals require treatment for chronic wounds. A recent systematic review of 11 studies reported a prevalence in the general population to be 2.21 and 1.51 per 1000 population for wounds of mixed etiology and chronic leg ulcers respectively [1]. Wound care has a huge economic impact on healthcare systems worldwide. An analysis of US Medicare claims for 2014 showed that 15 percent of beneficiaries (8.2 million) had an episode of care for a chronic wound or infection, with costs estimated between 28.1 to 96.8 billion [2]. In the UK, a study estimated that 4 percent of the total expenditure by the NHS in 2012/13 (5.3 billion pounds) went towards managing chronic wounds and associated morbidity for 2.2 million patients [3].

Chronic wounds have many different causes and numerous treatment modalities. The Cochrane Wounds review group, established in 1995, lists more than 150 protocols and reviews of the effects of interventions to prevent and treat wounds and their complications [4]. Outcome measures used in intervention studies tend to involve the use of objective measures (eg, healed wounds, rate of healing, adverse effects). The inclusion of carefully designed patient-reported outcome measures (PROMs) that ask about bothersome symptoms, such pain, exudate and odor, and the impact of wounds on aspects of quality of life, can provide important additional information from the patient perspective. Cochrane reviews of wound treatments show that such outcomes are often overlooked in treatment studies [e.g., 5-8].

PROMs that measure outcomes that matter to patient, as well as their experience of healthcare, are increasingly used to inform quality improvement initiatives, patient care, and comparative effectiveness research [9-11]. In chronic wounds, four reviews of PROMs have been published [12-15]. These reviews report that generic tools (e.g., SF-36, EQ-5D, Nottingham Health Profile) are often used. Such tools are limited in terms of content validity as they fail to ask about important wound-specific

1
2
3 issues (e.g., odor, exudate). In terms of wound-specific PROMs, most were developed for a specific type
4 of wound, including venous leg ulcers [16-22], foot ulcers [23-24] and pressure ulcers [25-26], or
5 wounds on specific parts of the body [27]. The Wound-QoL [27] represents an exception, as it was
6 designed for all types of chronic wounds. This 17-item instrument, published in 2014, was developed by
7 taking items from three existing PROMs, using factor analysis to determine how the items group
8 together, and then attaching labels (body, everyday life, and psyche) to each concept. The Wound-QoL
9 can be scored separately for each scale or by adding together the scales for a total score. Total scores are
10 hard to interpret (e.g., the direction and size of the scale scores can vary) and can be problematic in the
11 context of clinical trials.
12
13
14
15
16
17
18
19
20
21
22

23
24 Currently, there is no comprehensive PROM designed using a modern psychometric approach
25 covering all type of chronic wounds located anywhere on the body. The modern psychometric approach
26 uses more sophisticated models and techniques than the traditional approach, providing more diagnostic
27 details that aid in the refinement of scales that have interval (rather than ordinal) measurement properties
28 [29-30]. This protocol describes an international collaboration between investigators in Canada,
29 Denmark, the Netherlands, and the USA that aims to develop a new PROM (i.e., the WOUND-Q) for
30 evaluating outcomes in chronic wounds. We describe the mixed methods approach that we previously
31 published in the development of other Q-Portfolio instruments [31-33].
32
33
34
35
36
37
38
39
40
41

42 **METHODS AND ANALYSIS**

43
44 Development of the WOUND-Q follows guidelines for PROM development outlined by the Scientific
45 Advisory Committee of the Medical Outcomes Trust [34], the USA Food and Drug Administration [35],
46 and the International Society for Pharmacoeconomics and Outcomes Research [36-38]. We aim to
47 develop a self-report instrument for adults with any type of chronic wound located anywhere on the
48 body. Our goal is to develop a comprehensive set of independently functioning scales that measure
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 concepts of interest (COI) important to patients and healthcare providers working in chronic wound
4
5 care.
6

7
8 Our protocol covers a multi-phase mixed methods study that includes qualitative and quantitative
9
10 lines of inquiry. Figure 1 shows the three main phases involved in the development of a PRO
11
12 instrument. These phases include iterative steps for item generation, item reduction, and psychometric
13
14 validation. Careful adherence to the steps outlined in Figure 1 will ensure the WOUND-Q fulfills
15
16 minimum standards for acceptable psychometric properties described by the International Society for
17
18 Quality of Life Research (ISOQOL) [39] and the Consensus-based Standards for the Selection of Health
19
20 Status Measurement Instruments (COSMIN) [40-41].
21
22

23 24 **Phase 1: Qualitative**

25
26 We take a qualitative approach called Interpretive Description [42-43]. In our context, this applied
27
28 health services approach builds upon existing wound-specific theoretical knowledge, clinical
29
30 knowledge, and scientific research.
31
32

33 ***Sample***

34
35 Participants are purposively sampled to include a heterogeneous sample that varies by the following
36
37 characteristics: age (18 years and older), gender, wound type, wound location, phase in the healing
38
39 process, and risk of poor outcome (smokers and people with comorbid conditions such as diabetes and
40
41 obesity). Participants are recruited in wound care clinics by a member of the healthcare team who obtain
42
43 informed consent and pass contact details to a member of the research team to schedule interviews.
44
45

46
47 Phase 1 involves sites from Canada (University of St. Michael's College, Toronto), Denmark (Odense
48
49 University Hospital, Odense), The Netherlands (Catharina Hospital, Eindhoven; DaVinci Wound Clinic,
50
51 Geldrop), and the USA (University of California, Los Angeles Berkley East Nursing Home, Berkley,
52
53
54
55
56
57
58
59
60

1
2
3 and University of California, Los Angeles Medical Center, Santa Monica). Interviews are conducted
4
5 face-to-face or by phone depending on participant preference and logistics for travel.
6

7 ***Concept elicitation***

8
9
10 An interview guide (see Table 1) is used to guide the interviews. Topics are informed by published
11
12 wound-specific PROMs in the literature [13-15, 25, 28]. Interviews are audio-recorded and transcribed
13
14 verbatim. Interviews performed in Denmark and the Netherlands are translated into English by
15
16 professional translators and are coded by the local research team members. Data are coded line-by-line
17
18 whereby participant quotes are labelled with top level domains, themes, and subthemes. Data are moved
19
20 from Word to Excel for analysis. Participant characteristics are included in Excel to identify common
21
22 and unique COI by participant characteristics (e.g., wound type and location). Data analysis is done
23
24 concurrently with data collection to add new concepts to the interview guide for probing with new
25
26 participants. Sampling and recruitment continue until the point of saturation is reached, i.e., no further
27
28 new concepts elicited from additional interviews [44].
29
30
31
32

33 Rigor in the qualitative study is ensured by having one team member code the data and a second
34
35 team member confirm their analysis. Also, performing interviews and analysis at the same time for
36
37 member-checking takes place to confirm that the COI identified in interviews is confirmed in
38
39 subsequent interviews. Finally, peer debriefing is performed to verify the analysis between members of
40
41 the team members involved in coding as well as the full research team as described below.
42
43

44 Qualitative analysis leads to the refinement of a conceptual framework covering the main COI of
45
46 people with chronic wounds. This framework is used to guide scale development.
47
48

49 ***Item generation***

50
51 Participant quotes are used to create a comprehensive item pool. Items retain the language of
52
53 participants as much as possible to ensure that scale content is easy to understand and resonates with
54
55
56
57
58
59
60

1
2
3 patient experience. The item pool is sorted and analyzed by levels of coding (i.e., top level domains,
4 theme/subthemes) and participant characteristics (e.g., wound type) to identify common and unique COI
5
6 across. The item pool is used to develop a comprehensive set of independently functioning scales that
7
8 cover key aspects of the conceptual framework.
9
10

11 ***Scale development***

12
13 Scale development is informed by the Rasch Measurement Theory (RMT) approach [30, 45]. In this
14
15 approach, the item pool derived from the qualitative data is used to create, for each scale, a conformable
16
17 set of items that together map out a construct on a clinical hierarchy. Later in the study (phase 2), the
18
19 field-test data are analyzed to see if the theorized construct is supported by the data, i.e., do the data ‘fit’
20
21 the Rasch model. The pattern expected by the Rasch model follows a strict deterministic hierarchical
22
23 ordering of items called Guttman scaling. When the data fit the Rasch model, the estimates derived from
24
25 the model are considered appropriate, and it is legitimate to sum the items in a scale to obtain a total
26
27 score that provides interval-level measurement. Scales are assigned appropriate instructions and a time
28
29 frame for reporting. Each scale is assigned four or five labelled response options to keep them simple
30
31 and in line with published guidelines [46].
32
33
34
35
36

37 **Research team meeting**

38
39 After half the interviews are conducted and fully analyzed, a full day face-to-face research team meeting
40
41 is held to review the sample characteristics and data findings in order to identify and address gaps and
42
43 issues. At the meeting, the research team reviews codes, the item pool, and drafts scales that cover key
44
45 aspects of the preliminary conceptual framework. Following this meeting, interviews and analysis
46
47 continue until no new concepts are elicited from subsequent interviews.
48
49
50
51
52
53
54
55
56
57
58
59
60

Scale refinement

Scales are refined through multiple rounds of cognitive interviews [47-48] using the “think aloud” method [49]. The aim is to determine content validity, i.e., whether scale content is relevant, comprehensive, and comprehensible [41]. Participants from the initial interviews are invited to review the scales (English versions). Interviews are audio-recorded, transcribed, and analyzed line-by-line. Feedback on instructions, response options, and items are examined and used to revise the scales. Participants are encouraged to suggest missing issues that can be developed into items and added to scales.

Between rounds of cognitive interviews, the WOUND-Q is shown to experts for feedback. A web-based secure Research Electronic Data Capture (REDCap) survey is designed [50]. An international sample of wound experts are emailed the link to access the survey and provide feedback on the instructions, response options, and items, and to suggest missing content that could be formed into new items. One reminder email is sent after 10 days. Feedback provided by experts is used to revise the scales.

Translations

The WOUND-Q is translated into Danish and Dutch following steps outlined in Table 2. Translations follow guidelines set forth by the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [38] and the World Health Organization (WHO) [51]. These guidelines outline a rigorous process, previously used by our team [52], which involves two independent forward and one backward translation, an expert panel meeting, and a series of cognitive debriefing interviews with patients with chronic wounds. The aim is to create conceptually equivalent translations rather than literal translations. Producing more than one translation at the same time makes it possible to revise the items, instructions,

1
2
3 and response options of the WOUND-Q based on feedback from the translation work and to harmonize
4
5 the translations by comparing the Danish and Dutch with each other and with the English version.
6
7

8 **Phase II: Quantitative**

9
10 The phase II field-test study begins with a pilot field-test sample to identify any final changes to the
11
12 scales that are needed. Data from the first 250 participants are used to examine the psychometric
13
14 performance of each scale.
15

16
17 Phase II involves collection of data from a large international sample of patients with wounds
18
19 from sites in Canada (University of St. Michael's College, Toronto), Denmark (Odense University
20
21 Hospital, Odense), The Netherlands (Catharina Hospital, Eindhoven; DaVinci Wound Clinic, Geldrop;
22
23 Erasmus Medical Center, Rotterdam), and the USA (Brigham and Women's Hospital, Boston;
24
25 University of California, Los Angeles Berkley East Nursing Home, Berkley, and University of
26
27 California, Los Angeles Medical Center, Santa Monica). Additional sites can be added if needed to
28
29 ensure that the sample is large enough to explore how the items and scales function at the subgroup
30
31 level.
32
33

34
35 Participants are aged 18 years and older, cognitively able to self-report, and have one or more
36
37 chronic wounds anywhere on their body. A chronic wound is defined as a wound that has lasted 3
38
39 months or longer. Patients are recruited in hospital clinics by research assistants who obtain informed
40
41 consent. Data are collected using tablets with data entered into databases. REDCap databases are hosted
42
43 at Brigham and Women's Hospital in Boston (for the Canadian and USA data), and at Odense
44
45 University Hospital (for Danish data). In the Netherlands, data are collected using the Castor database.
46
47 Instructions with branching logic are used to ensure that only correct scales are administered to reduce
48
49 respondent burden.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Data collected via separate databases are merged using IBM SPSS Statistics V.25 and are
4
5 formatted appropriately for RUMM2030 software for RMT analysis [53]. The RMT analysis is used to
6
7 refine each scale and to create the scoring algorithms that future users of the scales will use. A range of
8
9 evidence is used to evaluate each item in a scale and examine how the items function as a set. Items that
10
11 are the most effective in measuring the concepts measured by a scale are retained. Items that do not
12
13 perform well are removed. Decisions are based on the following set of statistical and graphical tests are
14
15 used, and described in detail elsewhere [30]:

16
17
18
19 *Thresholds for item response options:* We examine thresholds between response options (eg, “not at all”
20
21 and “a little”) to determine if a scales response categories are ordered, meaning that a “1” on a 4-point
22
23 scale sits lower down a continuum than a “2,” etc. Items with disordered thresholds may be dropped or
24
25 recoded to ensure thresholds are properly ordered.

26
27
28 *Item fit statistics:* Three fit indicators are inspected including log residuals (item–person interaction),
29
30 Chi-square values (item–trait interaction), and item characteristic curves. As a guide, ideal fit residuals
31
32 are between -2.5 and $+2.5$, with Bonferroni adjusted Chi-square values non-significant. The three fit
33
34 indicators are interpreted together to decide items to retain or drop.

35
36
37
38 *Dependency:* Residual correlations between pairs of items are inspected to identify high residual
39
40 correlations as these can inflate reliability. For high residual correlations, a subtest is performed to
41
42 determine the impact on the reliability statistic (Person Separation Index).

43
44
45 *Targeting:* The location of items is examined to determine if they are evenly spread over a reasonable
46
47 range that matches the range of the construct reported by the sample. There should be minimal evidence
48
49 of a floor or ceiling effect so that people with a wide variety of wounds at different stages of healing can
50
51 be effectively measured over time.

1
2
3 *Differential item functioning (DIF)*: DIF is examined using ANOVA of item residuals to determine if
4 individuals in subgroups (e.g., sex, age, country, type of wound) respond differently to items despite the
5 same measured trait level. We choose random samples to create equal-sized subgroups. Items with Chi-
6 square values significant after Bonferroni adjustment are split on the variable that evidences DIF, and
7 the new and original person locations are correlated to examine impact on scoring.
8
9

10
11
12 *Unidimensionality*: We determine if all items in a scale measure the same, single latent construct using
13 the method proposed by Smith based on independent t-tests [54].
14

15
16
17 *Person separation index*: This reliability statistic measures error associated with the measurement of
18 people in a sample and is similar in interpretation to Cronbach α [55].
19
20
21
22

23
24 The minimum number of people needed to perform RMT analysis is 150 to have 50 respondents
25 in each of 3 class intervals for the Chi-square analysis for tests of item fit [56]. To examine DIF by
26 country will require 600 participants ($n=150$ per country). Our target is 250 per country to provide an
27 even more robust scoring algorithms and normative scores.
28
29
30
31
32

33 In IBM SPSS Statistics V.25, traditional psychometric properties are examined including
34 reliability (internal consistency), test-retest reproducibility (assessed 7 days after the initial completion),
35 and construct validity. Once item reduction and psychometric validation of the field-test data is
36 completed, the WOUND-Q will be made available for licensing through the Q-Portfolio website
37 (www.qportfolio.org).
38
39
40
41
42
43

44 **Subsequent phases**

45
46 We plan to seek grant funding to conduct a phase III study to examine further measurement properties
47 on the item-reduced scales, such as concurrent validity (the degree to which scores on an instrument
48 correlate with the Wound-QoL [27]), and to determine each scales' ability to measure clinical change
49 following wound treatment using anchor-based and distribution-based methods [57-59]. These studies
50
51
52
53
54
55
56
57
58
59
60

1
2
3 will be planned to reflect priorities identified by wound care teams and will utilize our international
4
5 network of wound care centres.
6

7 **Patient and public involvement**

8
9
10 Our approach to PROM development is patient-oriented as we engage a large sample of people with
11
12 wounds as well as clinical experts, in all stages of our research. Input from patients with chronic wounds
13
14 are indispensable to ensuring that the scales are developed to measure outcomes that matter to patients in
15
16 the language they use so that the final instrument resonates. Patients who take part in qualitative
17
18 interviews are invited to participate in the cognitive interviews as continuity of involvement ensures the
19
20 scales accurately reflect the experiences of patients living with chronic wounds. Involvement of experts
21
22 ensures that the scales will cover all clinically relevant outcomes and experiences of care.
23
24
25

26 **ETHICS**

27
28 This study is coordinated at Brigham and Women's Hospital (Boston, USA). Ethics board approval was
29
30 obtained from sites in Canada (University of St. Michael's College), The Netherlands (Catharina
31
32 Hospital, DaVinci Wound Clinic, and Erasmus Medical Center), and the USA (Brigham and Women's
33
34 Hospital, University of California, Los Angeles Berkley East Nursing Home, and University of
35
36 California, Los Angeles Medical Center). For Odense University Hospital in Denmark, we obtained
37
38 permission at the data protecting agency since ethics is not required for studies that involve
39
40 questionnaire surveys in Denmark.
41
42
43

44
45 Participants provide both written and oral consent before participating in an interview, and
46
47 written consent for participating in the field-test study. Participants in phase I are asked to discuss issues
48
49 that can be sensitive and they may experience distress. If necessary, we put participants in touch with a
50
51 healthcare provider at the recruiting site to obtain support. Participant data is de-identified during
52
53
54
55
56
57
58
59
60

1
2
3 transcription for the qualitative interviews. All data collected is kept secure and confidential following
4
5 institution rules governing research data storage.
6

7 **DISSEMINATION**

8
9
10 The WOUND-Q will be made available free of charge to all non-profit users. Our team will promote
11
12 uptake of the WOUND-Q among stakeholder groups including researchers, healthcare practitioners,
13
14 decision-makers, and policy-makers. Our dissemination initiatives will include face-to-face interactions
15
16 such as presentations at national and international meetings, as well as electronic and hard-copy media,
17
18 including publication in journals that are valued and read by our target audiences. The Q-Portfolio
19
20 website (www.qportfolio.org) and social media (e.g., Twitter, Instagram) will be used to spread
21
22 awareness of the WOUND-Q to our network of followers.
23
24
25
26
27

28 **FIGURE CAPTIONS**

29
30
31
32
33 Figure 1: Flow diagram illustrating the multiphase mixed methods approach to the development of the
34
35 WOUND-Q. QUAN, quantitative study component; QUAL, qualitative study component. Image
36
37 reproduced from Wong Riff et al [33]
38
39
40
41

42 Figure 2: Translation and cultural adaption steps for the WOUND-Q. Image reproduced from Van
43
44 Alphen et al [60]
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Martinengo L, Olsson M, Bajpai R, *et al*. Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies. *Ann Epidemiol* 2019;29:8–15. doi:[10.1016/j.annepidem.2018.10.005](https://doi.org/10.1016/j.annepidem.2018.10.005)
2. Nussbaum SR, Carter MJ, Fife CE, *et al*. An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. *Value Health* 2018;21:27–32. doi:[10.1016/j.jval.2017.07.007](https://doi.org/10.1016/j.jval.2017.07.007)
3. Guest JF, Ayoub N, McIlwraith T, *et al*. Health economic burden that wounds impose on the National Health Service in the UK. *BMJ Open* 2015;5:e009283. doi:[10.1136/bmjopen-2015-009283](https://doi.org/10.1136/bmjopen-2015-009283)
4. <https://wounds.cochrane.org/>. (Accessed May 2019).
5. Smith F, Dryburgh N, Donaldson J, *et al*. Debridement for surgical wounds. *Cochrane Database Syst Rev* 2013;9:CD006214. doi:[10.1002/14651858.CD006214.pub4](https://doi.org/10.1002/14651858.CD006214.pub4)
6. Kranke P, Bennett MH, Martyn-St James M, *et al*. Hyperbaric oxygen therapy for chronic wounds. *Cochrane Database Syst Rev* 2015;6:CD004123. doi:[10.1002/14651858.CD004123.pub4](https://doi.org/10.1002/14651858.CD004123.pub4)
7. Norman G, Westby MJ, Rithalia AD, *et al*. Dressings and topical agents for treating venous leg ulcers. *Cochrane Database Syst Rev* 2018;6:CD012583. doi:[10.1002/14651858.CD012583.pub2](https://doi.org/10.1002/14651858.CD012583.pub2)
8. Dumville JC, Webster J, Evans D, *et al*. Negative pressure wound therapy for treating pressure ulcers. *Cochrane Database Syst Rev* 2015;5:CD011334. doi:[10.1002/14651858.CD011334.pub2](https://doi.org/10.1002/14651858.CD011334.pub2)
9. Calvert M, Kyte D, Price G, *et al*. Maximising the impact of patient reported outcome assessment for patients and society. *BMJ* 2019;364:k5267. doi:[10.1136/bmj.k5267](https://doi.org/10.1136/bmj.k5267)
10. Nelson EC, Eftimovska E, Lind C, *et al*. Patient reported outcome measures in practice. *BMJ* 2015;350:g7818. doi:[10.1136/bmj.g7818](https://doi.org/10.1136/bmj.g7818)
11. Black N. Patient reported outcome measures could help transform healthcare. *BMJ* 2013;346:f167. doi:[10.1136/bmj.f167](https://doi.org/10.1136/bmj.f167)
12. Poku E, Aber A, Phillips P, *et al*. Systematic review assessing the measurement properties of patient-reported outcomes for venous leg ulcers. *BJS Open* 2017;1:138–47. doi:[10.1002/bjs5.25](https://doi.org/10.1002/bjs5.25)
13. Gorecki C, Brown JM, Cano S, *et al*. Development and validation of a new patient-reported outcome measure for patients with pressure ulcers: the PU-QOL instrument. *Health Qual Life Outcomes* 2013;11:95. doi:[10.1186/1477-7525-11-95](https://doi.org/10.1186/1477-7525-11-95)
14. González-Consuegra RV, Verdú J. Quality of life in people with venous leg ulcers: an integrative review. *J Adv Nurs* 2011;67:926–44. doi:[10.1111/j.1365-2648.2010.05568.x](https://doi.org/10.1111/j.1365-2648.2010.05568.x)
15. Palfreyman SJ, Tod AM, Brazier JE, *et al*. A systematic review of health-related quality of life instruments used for people with venous ulcers: an assessment of their suitability and psychometric properties. *J Clin Nurs* 2010;19:2673–703. doi:[10.1111/j.1365-2702.2010.03269.x](https://doi.org/10.1111/j.1365-2702.2010.03269.x)
16. Hyland ME, Ley A, Thomson B. Quality of life of leg ulcer patients: questionnaire and preliminary findings. *J Wound Care* 1994;3:294–8. doi:[10.12968/jowc.1994.3.6.294](https://doi.org/10.12968/jowc.1994.3.6.294)

17. Hareendran A, Doll H, Wild DJ, *et al*. The venous leg ulcer quality of life (VLU-QoL) questionnaire: development and psychometric validation. *Wound Repair Regen* 2007;**15**:465–73. doi:[10.1111/j.1524-475X.2007.00253.x](https://doi.org/10.1111/j.1524-475X.2007.00253.x)
18. Smith JJ, Guest MG, Greenhalgh RM, *et al*. Measuring the quality of life in patients with venous ulcers. *J Vasc Surg* 2000;**31**:642–9. doi:[10.1067/mva.2000.104103](https://doi.org/10.1067/mva.2000.104103)
19. Pilot study investigating the feasibility of an ulcer-specific quality of life questionnaire. *Phlebology* 2005;**20**:14–27. doi:[10.1258/0268355053300839](https://doi.org/10.1258/0268355053300839)
20. Palfreyman S, Michaels J, Brazier J. Development of a tool to examine the effect of venous ulcers on patients' quality of life. *Nurs Stand* 2007;**21**:57–8. doi:[10.7748/ns2007.07.21.45.57.c4585](https://doi.org/10.7748/ns2007.07.21.45.57.c4585)
21. Bland JM, Dumville JC, Ashby RL, *et al*. Validation of the VEINES-QOL quality of life instrument in venous leg ulcers: repeatability and validity study embedded in a randomised clinical trial. *BMC Cardiovasc Disord* 2015;**15**:85. doi:[10.1186/s12872-015-0080-7](https://doi.org/10.1186/s12872-015-0080-7)
22. Brown A, Kendall S, Flanagan M, *et al*. Encouraging patients to self-care - the preliminary development and validation of the VeLUSET©, a self-efficacy tool for venous leg ulcer patients, aged 60 years and over. *Int Wound J* 2014;**11**:326–34. doi:[10.1111/iwj.12199](https://doi.org/10.1111/iwj.12199)
23. Abetz L, Sutton M, Brady L, *et al*. The Diabetic Foot Ulcer Scale (DFS): a quality of life instrument for use in clinical trials. *Practical Diabetes Int* 2002;**19**:167–75. doi:[10.1002/pdi.356](https://doi.org/10.1002/pdi.356)
24. Vileikyte L, Peyrot M, Bundy C, *et al*. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. *Diabetes Care* 2003;**26**:2549–55. doi:[10.2337/diacare.26.9.2549](https://doi.org/10.2337/diacare.26.9.2549)
25. Gorecki C, Nixon J, Lamping DL, *et al*. Patient-reported outcome measures for chronic wounds with particular reference to pressure ulcer research: a systematic review. *Int J Nurs Stud* 2014;**51**:157–65. doi:[10.1016/j.ijnurstu.2013.03.004](https://doi.org/10.1016/j.ijnurstu.2013.03.004)
26. Kisala PA, Tulskey DS, Choi SW, *et al*. Development and psychometric characteristics of the SCI-QOL Pressure Ulcers scale and short form. *J Spinal Cord Med* 2015;**38**:303–14. doi:[10.1179/2045772315Y.0000000017](https://doi.org/10.1179/2045772315Y.0000000017)
27. Price P, Harding K. Cardiff Wound Impact Schedule: the development of a condition-specific questionnaire to assess health-related quality of life in patients with chronic wounds of the lower limb. *Int Wound J* 2004;**1**:10–7. doi:[10.1111/j.1742-481x.2004.00007.x](https://doi.org/10.1111/j.1742-481x.2004.00007.x)
28. Blome C, Baade K, Debus ES, *et al*. The “Wound-QoL”: A short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. *Wound Repair Regen* 2014;**22**:504–14. doi:[10.1111/wrr.12193](https://doi.org/10.1111/wrr.12193)
29. Petrillo J, Cano SJ, McLeod LD, *et al*. Using classical test theory, item response theory, and Rasch measurement theory to evaluate patient-reported outcome measures: a comparison of worked examples. *Value Health* 2015;**18**:25–34. doi:[10.1016/j.jval.2014.10.005](https://doi.org/10.1016/j.jval.2014.10.005)
30. Hobart J, Cano S. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. *Health Technol Assess* 2009;**13**:iii, ix–x, 1–177. doi:[10.3310/hta13120](https://doi.org/10.3310/hta13120)

31. Sierakowski K, Dean NR, Pusic AL, *et al.* International multiphase mixed methods study protocol to develop a cross-cultural patient-reported outcome and experience measure for hand conditions (HAND-Q). *BMJ Open* 2019;**9**:e025822. doi:[10.1136/bmjopen-2018-025822](https://doi.org/10.1136/bmjopen-2018-025822)
32. Klassen AF, Kaur M, Johnson N, *et al.* International phase I study protocol to develop a patient-reported outcome measure for adolescents and adults receiving gender-affirming treatments (the GENDER-Q). *BMJ Open* 2018;**8**:e025435. doi:[10.1136/bmjopen-2018-025435](https://doi.org/10.1136/bmjopen-2018-025435)
33. Wong Riff K W Y, Tsangaris E, Goodacre T, *et al.* International multiphase mixed methods study protocol to develop a cross-cultural patient-reported outcome instrument for children and young adults with cleft lip and/or palate (CLEFT-Q). *BMJ Open* 2017;**7**:e015467. doi:[10.1136/bmjopen-2016-015467](https://doi.org/10.1136/bmjopen-2016-015467)
34. Aaronson N, Alonso J, Burnam A, *et al.* Assessing health status and quality-of-life instruments: attributes and review criteria. *Qual Life Res* 2002;**11**:193–205.
35. US Department of Health and Human Services. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available at: <https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf> (accessed May 2019).
36. Patrick DL, Burke LB, Gwaltney CJ, *et al.* Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. *Value Health* 2011;**14**:967–77. doi:[10.1016/j.jval.2011.06.014](https://doi.org/10.1016/j.jval.2011.06.014)
37. Patrick DL, Burke LB, Gwaltney CJ, *et al.* Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. *Value Health* 2011;**14**:978–88. doi:[10.1016/j.jval.2011.06.013](https://doi.org/10.1016/j.jval.2011.06.013)
38. Wild D, Grove A, Martin M, *et al.* Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. *Value Health* 2005;**8**:94–104. doi:[10.1111/j.1524-4733.2005.04054.x](https://doi.org/10.1111/j.1524-4733.2005.04054.x)
39. Reeve BB, Wyrwich KW, Wu AW, *et al.* ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. *Qual Life Res* 2013;**22**:1889–905. doi:[10.1007/s11136-012-0344-y](https://doi.org/10.1007/s11136-012-0344-y)
40. Mokkink LB, Terwee CB, Patrick DL, *et al.* The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. *Qual Life Res* 2010;**19**:539–49. doi:[10.1007/s11136-010-9606-8](https://doi.org/10.1007/s11136-010-9606-8)
41. Terwee CB, Prinsen C a. C, Chiarotto A, *et al.* COSMIN methodology for evaluating the content validity of patient-reported outcomes measures: a Delphi study. *Qual Life Res* 2018;**27**:1159–70. doi:[10.1007/s11136-018-1829-0](https://doi.org/10.1007/s11136-018-1829-0)
42. Thorne S, Kirkham SR, MacDonald-Emes J. Interpretive description: A noncategorical qualitative alternative for developing nursing knowledge. *Res Nurs Health* 1997;**20**:169–77. doi:[10.1002/\(SICI\)1098-240X\(199704\)20:2<169::AID-NUR9>3.0.CO;2-I](https://doi.org/10.1002/(SICI)1098-240X(199704)20:2<169::AID-NUR9>3.0.CO;2-I)

- 1
2
3 43. Thorne SE. Interpretive description. Developing qualitative inquiry, vol 2. Walnut Creek (CA): Left
4 Coast Press, 2008.
5
6 44. Given LM, Sandelowski M. Theoretical Saturation. In: Given LM, ed. The SAGE Encyclopedia of
7 Qualitative Research Methods. Thousand Oaks: SAGE Publications, Inc. 2008. 876–876.
8 doi:[10.4135/9781412963909](https://doi.org/10.4135/9781412963909)
9
10 45. Rasch G. Studies in mathematical psychology: 1. Probabilistic Models for Some Intelligence and
11 Attainment Tests. Copenhagen: Danmarks pædagogiske Institut. 1960.
12
13 46. Khadka J, Gothwal VK, McAlinden C, *et al*. The importance of rating scales in measuring patient-
14 reported outcomes. *Health Qual Life Outcomes* 2012;**10**:80. doi:[10.1186/1477-7525-10-80](https://doi.org/10.1186/1477-7525-10-80)
15
16 47. Willis GB. Cognitive interviewing: A tool for improving questionnaire design. Thousand Oaks, CA:
17 Sage Publications 2005.
18
19 48. Collins D. Pretesting survey instruments: An overview of cognitive methods. *Qual Life Res*
20 2003;**12**:229–38. doi:[10.1023/A:1023254226592](https://doi.org/10.1023/A:1023254226592)
21
22 49. Van Someren M, Barnard Y, Sandberg J. The think-aloud method. London: Academic Press; 1994.
23
24 50. Harris PA, Taylor R, Thielke R, *et al*. Research electronic data capture (REDCap)--a metadata-
25 driven methodology and workflow process for providing translational research informatics support. *J*
26 *Biomed Inform* 2009;**42**:377–81. doi:[10.1016/j.jbi.2008.08.010](https://doi.org/10.1016/j.jbi.2008.08.010)
27
28 51. WHO (World Health Organization). The process of translation and adaptation of instruments.
29 Available at: http://www.who.int/substance_abuse/research_tools/translation/en/ (accessed May
30 2019)
31
32 52. Poulsen L, Rose M, Klassen A, *et al*. Danish translation and linguistic validation of the BODY-Q: a
33 description of the process. *Eur J Plast Surg* 2017;**40**:29–38. doi:[10.1007/s00238-016-1247-x](https://doi.org/10.1007/s00238-016-1247-x)
34
35 53. RUMM Lab. <http://www.rummlab.com.au/> (accessed 29 May 2019).
36
37 54. Smith EV. Detecting and evaluating the impact of multidimensionality using item fit statistics and
38 principal component analysis of residuals. *J Appl Meas* 2002;**3**:205–31.
39
40 55. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill, 1994.
41
42 56. Sample Size and Item Calibration or Person Measure Stability. Available at:
43 <http://www.rasch.org/rmt/rmt74m.htm> (accessed May 2019)
44
45 57. Terwee CB, Dekker FW, Wiersinga WM, *et al*. On assessing responsiveness of health-related
46 quality of life instruments: guidelines for instrument evaluation. *Qual Life Res* 2003;**12**:349–62. doi:
47 [10.1023/A:1023499322593](https://doi.org/10.1023/A:1023499322593)
48
49 58. Husted JA, Cook RJ, Farewell VT, *et al*. Methods for assessing responsiveness: a critical review and
50 recommendations. *J Clin Epidemiol* 2000;**53**:459–68. doi: [10.1016/S0895-4356\(99\)00206-1](https://doi.org/10.1016/S0895-4356(99)00206-1)
51
52 59. Brozek JL, Guyatt GH, Schünemann HJ. How a well-grounded minimal important difference can
53 enhance transparency of labelling claims and improve interpretation of a patient reported outcome
54 measure. *Health Qual Life Outcomes* 2006;**4**:69. doi:[10.1186/1477-7525-4-69](https://doi.org/10.1186/1477-7525-4-69)
55
56 60. Van Alphen TC, Poulsen L, van Haren ELWG, *et al*. Danish and Dutch linguistic validation and
57 cultural adaptation of the WOUND-Q, a PROM for chronic wounds. *Eur J Plast Surg* 2019:1-10.
58 doi:[10.1007/s00238-019-01529-7](https://doi.org/10.1007/s00238-019-01529-7)
59
60

Table 1: WOUND-Q interview guide**Wound**

1. How did your wound originate? Probe: any comorbid diabetes, obesity
2. Can you tell me about any wounds you've had in the past?
3. How was the healing process for you? Probe: hemostasis, inflammation, proliferation, and remodeling

Treatments

4. What treatment(s) have you had for your wound?
5. What was good/bad about the treatment(s)? Probe: side effects

Symptoms

6. Can you describe any symptoms you experience? Probe: e.g., pain, odor, exudate
7. Have symptoms changed over time? Probe: hemostasis, inflammation, proliferation, and remodeling
8. How bothersome are the symptoms?
9. How do you cope with the symptoms?

Recovery

10. How quickly did you recover?
11. What was the recovery process like? Probe: hemostasis, inflammation, proliferation, and re-modelling
12. Can you describe the early life impact? Probe: impact on physical, social, emotional, social life

Appearance

13. How would you describe the appearance of your wound? Probe for descriptive detail.
14. What do you like/dislike about the appearance of your wound?
15. How has your appearance changed? Probe hemostasis, inflammation, proliferation, and remodeling
16. Is there anything about the wound you wish looked different? Probe for descriptive detail.
17. Do/did you ever hide or cover your wound? How do you do this?

Physical Function

18. Does the wound create physical issues? Probe: e.g., mobility, activity limitations
19. How have these physical issues changed? Probe hemostasis, inflammation, proliferation, remodeling

Psychological Wellbeing

20. How does your wound affect how you feel? Probe: happy, sad, anxious, frustrated, self-conscious.
21. How does your wound affect how you feel about yourself? Probe: self-esteem; body image; confidence.
22. How have your emotions changed? Probe hemostasis, inflammation, proliferation, remodeling

Social Life


23. What has it been like for you at home? Probe: partner, family, children.
24. Has the wound affected your usual activities? Probe: work/education?
25. Do people ever comment on your wound? Probe: how did you react; how did you feel?
26. Are there things you would have liked to do but don't because of your wound?
27. Has anyone ever treated you differently because of your wound? Probe: friends, family, strangers.
28. How else does your wound affect your social life? Probe: with friends, meeting new people, dating.

Experience of Care

29. Who did you see at the hospital or clinic? Probe: doctor, nurse, receptionist, etc.
30. What are the people like who cared for you? Probe: friendly; made you feel comfortable; easy to talk to; listened to you; respectful; available.
31. What kind of verbal and written information did you receive? Probe: gave enough information; let you ask questions; answered your questions; information about recovery; treatment information
32. What things could the healthcare team do differently to improve the care you received?
33. What should the perfect wound healing center be like?

Other Questions


34. Is there anything I have not asked you that you think it is important for me to know?



Flow diagram illustrating the multiphase mixed methods approach to the development of the WOUND-Q. QUAN, quantitative study component; QUAL, qualitative study component. Image reproduced from Wong Riff et al [33]

78x108mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Translation and cultural adaption steps for the WOUND-Q. Image reproduced from Van Alphen et al [60]

BMJ Open

International Mixed Methods Study Protocol to Develop a Patient-Reported Outcome Measure for all Types of Chronic Wounds (the WOUND-Q)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032332.R1
Article Type:	Protocol
Date Submitted by the Author:	06-Dec-2019
Complete List of Authors:	Klassen, Anne; McMaster University, Pediatrics van Haren, Emiel; Catharina Ziekenhuis, Plastic and Reconstructive Surgery, Cross, Karen; St Michael's Hospital, Plastic Surgery Fan, Kenneth; MedStar Georgetown University Hospital, Plastic and Reconstructive Surgery Gibbons, Chris; Harvard Medical School, Faculty of Medicine Hoogbergen, Maarten; Catharina Ziekenhuis Longmire, Natasha; McMaster University Poulsen, Lotte; University of Southern Denmark Sorensen, Jens; Odense University Hospital Squitieri, Lee; University of Southern California Tsangaris, Elena; Brigham and Women's Hospital van Alphen, Tert; Catharina Ziekenhuis van Dishoeck, Anne-Margreet; Erasmus Medical Center, Plastic and Reconstructive Surgery Vasilic, Dali; Erasmus Medical Center, Plastic Surgery Pusic, Andrea; Brigham and Women's Hospital Biomedical Research Institute
Primary Subject Heading:	Surgery
Secondary Subject Heading:	Qualitative research, Health services research
Keywords:	patient-reported outcome, quality of life, psychometrics, Rasch, WOUND MANAGEMENT, PLASTIC & RECONSTRUCTIVE SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title:** International Mixed Methods Study Protocol to Develop a Patient-Reported Outcome Measure for
4 all Type of Chronic Wounds (the WOUND-Q)
5
6
7

8
9 **Authors:**
10

- 11
12 1. Anne F. Klassen DPhil, Department of Pediatrics, McMaster University, 3N27, 1280 Main Street W,
13
14 Hamilton, ON, Canada
- 15
16 2. Emiel LWG van Haren MD, Department of Plastic and Reconstructive Surgery, Catharina
17
18 Ziekenhuis, Eindhoven, the Netherlands
- 19
20 3. Karen Cross MD PhD, Department of Plastic Surgery, St. Michael's Hospital and Keenan Research
21
22 Centre, Toronto, Ontario, Canada
- 23
24 4. Kenneth L Fan MD, Department of Plastic and Reconstructive Surgery, MedStar Georgetown
25
26 University Hospital, Washington, DC, USA
- 27
28 5. Chris Gibbons PhD, Department of Surgery, Brigham and Women's Hospital, 75 Francis S, Boston,
29
30 MA, USA
- 31
32 6. Maarten M Hoogbergen MD PhD, Department of Plastic and Reconstructive Surgery, Catharina
33
34 Ziekenhuis, Eindhoven, the Netherlands
- 35
36 7. Natasha Longmire MSc, Department of Psychology, University of Toronto, Toronto, ON, Canada
- 37
38 8. Lotte Poulsen MD, Department of Plastic and Reconstructive Surgery, University of Southern
39
40 Denmark, Odense, Denmark
- 41
42 9. Jens Ahm Sørensen MD PhD, Department of Plastic and Reconstructive Surgery, Odense University
43
44 Hospital, Odense, Denmark
- 45
46 10. Lee Squitieri MD, PhD, MS, Division of Plastic and Reconstructive Surgery, University of Southern
47
48 California, Los Angeles, CA, USA
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 11. Elena Tsangaris PhD, Department of Surgery, Brigham and Women's Hospital, 75 Francis St,
4
5 Boston, MA, USA
6

7
8 12. Tert C van Alphen MD, MBA, Department of Plastic and Reconstructive Surgery, Catharina
9
10 Ziekenhuis, Eindhoven, The Netherlands
11

12
13 13. Anne-Margreet van Dishoeck PhD, Department of Plastic and Reconstructive Surgery, Erasmus
14
15 Medical Center, Rotterdam, The Netherlands
16

17
18 14. Dali Vasilic MD, PhD, Department of Plastic and Reconstructive Surgery, Erasmus Medical Center,
19
20 Rotterdam, The Netherlands
21

22
23 15. Andrea L Pusic MD MSc, Department of Surgery, Brigham and Women's Hospital, 75 Francis S,
24
25 Boston, MA, USA
26

27
28 **Corresponding Author:** Andrea Pusic MD MSc, Department of Surgery Brigham and Women's
29
30 Hospital, 75 Francis S, Boston, MA, USA, 02116, apusic@bwh.harvard.edu
31

32
33 **Funding Statement:** Phases I and II of this study are funded by research grants received from the
34
35 Plastic Surgery Foundation (120593). The authors have no financial interest to declare in relation to the
36
37 content of this article. The Article Processing Charge was paid from the Plastic Surgery Foundation
38
39 grant.
40
41

42
43 **Contributions:** AFK, ALP conceived and designed the study. AFK, ELWGvH, KC, CG, MMH, NL,
44
45 LP, JS, LS, ET, TCvA, AvD, DV, ALP revised the article critically for important intellectual content
46
47 and have approved the final version to be published.
48
49

50
51 **Competing Interests Statement:** The WOUND-Q will be owned by Memorial Sloan-Kettering Cancer
52
53 Center. Drs. Pusic and Klassen are co-developers of other Q-Portfolio instruments and receive a share of
54
55

1
2
3 any license revenue on the inventor sharing policies of the institutions that own them. The remaining
4
5 authors have no conflict of interest to declare. **Word count = (maximum 4000)**
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT = 270 of 300

Introduction: Most patient-reported outcome measures (PROM) for chronic wounds are specific to a single wound type (e.g., pressure ulcer) or part of the body. A barrier to outcome assessment in wound care and research is the lack of a rigorously-designed PROM that can be used across wound types and locations. This mixed method study describes the protocol for an international collaboration to develop and validate a new PROM called the WOUND-Q.

Methods and analysis: In phase 1, the qualitative approach of interpretive description is used to elicit concepts important to people with wounds regarding outcome. Participants from Canada, Denmark, the Netherlands, and the USA are aged 18 years and older and have a wound that has lasted 3 months or longer. Interviews are digitally recorded, transcribed and coded. A conceptual framework and preliminary item pool are developed from the qualitative dataset. Draft scales are formed to cover important themes in the conceptual framework. These scales are refined using feedback from people with chronic wounds and wound care experts. After refinement, the scales are translated into Danish and Dutch following rigorous methods to prepare for the international field-test study. In phase II, data are collected in Canada, Denmark, the Netherlands, and the USA. An international sample of people with a large variety of chronic wounds complete the WOUND-Q. Rasch Measurement Theory analysis is used to identify the best subset of items to retain for each scale and to examine reliability and validity.

Ethics and dissemination: This study is coordinated at Brigham and Women's Hospital (Boston, USA). Ethics board approval was received at each participating site for both study phases. Findings will be published in peer-reviewed journals and presented at national and international conferences and meetings.

Strengths and limitations of this study

- Recruitment of an international sample makes it possible to develop a patient-reported outcome measure (PROM) that reflects the concerns of patients in multiple countries.
- Including people with varying types of chronic wounds in different locations on the body ensures that the WOUND-Q is broadly applicable.
- We adhere to published guidelines for PROM development, including rigorous methods for translation and cultural adaptation.
- We use a modern psychometric approach (Rasch Measurement Theory) to enhance the interpretability of WOUND-Q scores.
- A limitation of our study is that patient involvement does not include membership in the research team. Another limitation is that the WOUND-Q field-test takes place only in high income countries.

INTRODUCTION

Each year, millions of individuals require treatment for chronic wounds. A recent systematic review of 11 studies reported a prevalence in the general population to be 2.21 and 1.51 per 1000 population for wounds of mixed etiology and chronic leg ulcers respectively [1]. Wound care has a huge economic impact on healthcare systems worldwide. An analysis of US Medicare claims for 2014 showed that 15 percent of beneficiaries (8.2 million) had an episode of care for a chronic wound or infection, with costs estimated between 28.1 to 96.8 billion [2]. In the UK, a study estimated that 4 percent of the total expenditure by the NHS in 2012/13 (5.3 billion pounds) went towards managing chronic wounds and associated morbidity for 2.2 million patients [3].

Chronic wounds have many different causes and numerous treatment modalities. The Cochrane Wounds review group, established in 1995, lists more than 150 protocols and reviews of the effects of interventions to prevent and treat wounds and their complications [4]. Outcome measures used in intervention studies tend to involve the use of objective measures (eg, healed wounds, rate of healing, adverse effects). The inclusion of carefully designed patient-reported outcome measures (PROMs) that ask about concerns that matter the most to patients, including bothersome symptoms, such pain, exudate and odor, and the impact of wounds on aspects of quality of life, can provide important additional information from the patient perspective. Cochrane reviews of wound treatments show that such outcomes are often overlooked in treatment studies [e.g., 5-8].

PROMs that measure outcomes that matter to patient, as well as their experience of healthcare, are increasingly used to inform quality improvement initiatives, patient care, and comparative effectiveness research [9-11]. In chronic wounds, four reviews of PROMs have been published [12-15]. These reviews report that generic tools (e.g., SF-36, EQ-5D, Nottingham Health Profile) are often used. Such tools are limited in terms of content validity as they fail to ask about important wound-specific

1
2
3 issues (e.g., odor, exudate). In terms of wound-specific PROMs, most were developed for a specific type
4 of wound, including venous leg ulcers [16-22], foot ulcers [23-24] and pressure ulcers [25-26], or
5 wounds on specific parts of the body [27]. The Wound-QoL [28] represents an exception, as it was
6 designed for all types of chronic wounds. This 17-item instrument, published in 2014, was developed by
7 taking items from three existing PROMs, using factor analysis to determine how the items group
8 together, and then attaching labels (body, everyday life, and psyche) to each concept. The Wound-QoL
9 can be scored separately for each scale or by adding together the scales for a total score.

19 PROMs that add scales together for a total score can be problematic because the concept of
20 interest measured by the instrument may not be clear. The same is true for PROMs that score each scale
21 separately if the scales are composed of item sets that ask about multiple concepts of interest. For
22 example, the body scale from the Wound-QoL has five items that measures a range of concepts,
23 including pain, wound discharge and problems sleeping [28]. Item sets that ask about multiple concepts
24 are limited in their ability to measure change in specific issues. In the context of a clinical trial, such
25 scales can mask effects of treatment (e.g., when the direction and size of the scores vary by concept).
26 The alternative approach is to design a set of independently functioning scales that each measure a
27 unidimensional construct, e.g., discharge, smell, sleep interference, etc. An advantage of this approach is
28 that respondent burden can be decreased as only the scales that are relevant to a particular research
29 question or clinical scenario need to be used.

44 Currently, there is no comprehensive PROM designed using a modern psychometric approach
45 covering all type of chronic wounds located anywhere on the body. The modern psychometric approach
46 uses more sophisticated models and techniques than the traditional approach, providing more diagnostic
47 details that aid in the refinement of scales that have interval (rather than ordinal) measurement properties
48 [29-30]. This protocol describes an international collaboration between investigators in Canada,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Denmark, the Netherlands, and the USA that aims to develop a new PROM (i.e., the WOUND-Q) for
4 patients with chronic wounds. The WOUND-Q will contain a comprehensive set of independently
5 functioning scales designed to measure outcomes that matter to patients with any type of chronic wound,
6 as well as scales to measure patients experience of wound care. We describe the mixed methods
7 approach that we previously published in the development of other Q-Portfolio instruments [31-33].
8
9
10
11
12
13

14 **METHODS AND ANALYSIS**

15
16 Development of the WOUND-Q follows guidelines for PROM development outlined by the Scientific
17 Advisory Committee of the Medical Outcomes Trust [34], the USA Food and Drug Administration [35],
18 and the International Society for Pharmacoeconomics and Outcomes Research [36-38]. We aim to
19 develop a self-report instrument for adults with any type of chronic wound located anywhere on the
20 body. Our goal is to develop a comprehensive set of independently functioning scales that measure
21 concepts of interest (COI) important to patients and healthcare providers working in chronic wound
22 care.
23
24
25
26
27
28
29
30
31
32

33 Our protocol covers a multi-phase mixed methods study that includes qualitative and quantitative
34 lines of inquiry. Figure 1 shows the three main phases involved in the development of a PROM [33].
35 These phases include iterative steps for item generation, item reduction, and psychometric validation.
36 Careful adherence to the steps outlined in Figure 1 will ensure the WOUND-Q fulfills minimum
37 standards for acceptable psychometric properties described by the International Society for Quality of
38 Life Research (ISOQOL) [39] and the Consensus-based Standards for the Selection of Health Status
39 Measurement Instruments (COSMIN) [40-41].
40
41
42
43
44
45
46
47
48

49 **Phase 1: Qualitative**

1
2
3 We take a qualitative approach called Interpretive Description [42-43]. In our context, this applied
4
5 health services approach builds upon existing wound-specific theoretical knowledge, clinical
6
7 knowledge, and scientific research.
8
9

10 ***Sample***

11
12 Participants are purposively sampled to include a heterogeneous sample that varies by the following
13
14 characteristics: age (18 years and older), gender, wound type, wound location, phase in the healing
15
16 process, and risk of poor outcome (smokers and people with comorbid conditions such as diabetes and
17
18 obesity). Participants are recruited in wound care clinics by a member of the healthcare team who obtain
19
20 informed consent and pass contact details to a member of the research team to schedule interviews.
21
22

23
24 Phase 1 involves sites from Canada (University of St. Michael's College, Toronto), Denmark (Odense
25
26 University Hospital, Odense), The Netherlands (Catharina Hospital, Eindhoven; DaVinci Wound Clinic,
27
28 Geldrop), and the USA (University of California, Los Angeles Berkley East Nursing Home, Berkley,
29
30 and University of California, Los Angeles Medical Center, Santa Monica). Interviews are conducted
31
32 face-to-face or by phone depending on participant preference and logistics for travel.
33
34

35 ***Concept elicitation***

36
37 An interview guide (see Table 1) is used to guide the interviews. Topics are informed by published
38
39 wound-specific PROMs in the literature [13-15, 25, 28]. Interviews are audio-recorded and transcribed
40
41 verbatim. Interviews performed in Denmark and the Netherlands are translated into English by
42
43 professional translators and are coded by the local research team members. Data are coded line-by-line
44
45 whereby participant quotes are labelled with top level domains, themes, and subthemes. Data are moved
46
47 from Word to Excel for analysis. Participant characteristics are included in Excel to identify common
48
49 and unique COI by participant characteristics (e.g., wound type and location). Data analysis is done
50
51 concurrently with data collection to add new concepts to the interview guide for probing with new
52
53
54
55
56
57
58
59
60

1
2
3 participants. Sampling and recruitment continue until the point of saturation is reached, i.e., no further
4
5 new concepts elicited from additional interviews [44].
6

7
8 Rigor in the qualitative phase of the study is ensured by having one team member code the
9
10 qualitative transcripts and a second team member confirm the codes. Also, performing qualitative
11
12 interviews and analysis at the same time makes it possible add COIs important to participants in earlier
13
14 interviews to the interview guide in order to explore if the COIs are important to participants in
15
16 subsequent interviews. Finally, peer debriefing is performed to verify the analysis of the qualitative data
17
18 between members of the team members who perform the coding, as well as with the full research team
19
20 at the research team meeting described below.
21
22

23
24 Qualitative analysis leads to the refinement of a conceptual framework covering the main COI of
25
26 people with chronic wounds. This framework is used to guide scale development.
27

28 ***Item generation***

29
30 Participant quotes are used to create a comprehensive item pool. Items retain the language of
31
32 participants as much as possible to ensure that scale content is easy to understand and resonates with
33
34 patient experience. The item pool is sorted and analyzed by levels of coding (i.e., top level domains,
35
36 theme/subthemes) and participant characteristics (e.g., wound type) to identify common and unique COI
37
38 across. The item pool is used to develop a comprehensive set of independently functioning scales that
39
40 cover key aspects of the conceptual framework.
41
42
43

44 ***Scale development***

45
46 Scale development is informed by the Rasch Measurement Theory (RMT) approach [30, 45]. In this
47
48 approach, a pool of items that are reflective of the underlying constructs are derived from the qualitative
49
50 data to create, for each scale, a conformable set of items that together map out a construct on a clinical
51
52 hierarchy. Later in the study (phase 2), the field-test data are analyzed to see if the theorized construct is
53
54
55
56
57
58
59

1
2
3 supported by the data, i.e., do the data ‘fit’ the Rasch model. The pattern expected by the Rasch model
4 follows a strict deterministic hierarchical ordering of items called Guttman scaling. When the data fit the
5 Rasch model, the estimates derived from the model are considered appropriate, and it is legitimate to
6 sum the items in a scale to obtain a total score that provides interval-level measurement. Scales are
7 assigned appropriate instructions and a time frame for reporting. Each scale is assigned four or five
8 labelled response options to keep them simple and in line with published guidelines [46].
9

16 **Research team meeting**

17
18 After half the interviews are conducted and fully analyzed, a full day face-to-face research team meeting
19 is held to review the sample characteristics and data findings in order to identify and address gaps and
20 issues. At the meeting, wound care experts and the research team reviews codes, the item pool, and
21 drafts scales that cover key aspects of the preliminary conceptual framework. Following this meeting,
22 interviews and analysis continue until no new concepts are elicited from subsequent interviews.
23
24
25
26
27
28
29

30 **Scale refinement**

31
32 Scales are refined through multiple rounds of cognitive interviews [47-48] using the “think aloud”
33 method [49]. The aim is to determine content validity, i.e., whether scale content is relevant,
34 comprehensive, and comprehensible [41]. Participants from the initial interviews are invited to review
35 the scales (English versions). Interviews are audio-recorded, transcribed, and analyzed line-by-line.
36 Feedback on instructions, response options, and items are examined and used to revise the scales.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Between rounds of cognitive interviews, the WOUND-Q is shown to experts for feedback. A
web-based secure Research Electronic Data Capture (REDCap) survey is designed [50]. An
international sample of wound experts are emailed the link to access the survey and provide feedback on

1
2
3 the instructions, response options, and items, and to suggest missing content that could be formed into
4 new items. One reminder email is sent after 10 days. Feedback provided by experts is used to revise the
5
6
7 scales.

10 **Translations**

11
12 The WOUND-Q is translated into Danish and Dutch following steps outlined in Figure 2 [51].

13
14 Translations follow guidelines set forth by the International Society for Pharmacoeconomics and
15 Outcomes Research (ISPOR) [38] and the World Health Organization (WHO) [52]. These guidelines
16
17 outline a rigorous process, previously used by our team [53], which involves two independent forward
18
19 and one backward translation, an expert panel meeting, and a series of cognitive debriefing interviews
20
21 with patients with chronic wounds. The aim is to create conceptually equivalent translations rather than
22
23 literal translations. Producing more than one translation at the same time makes it possible to revise the
24
25 items, instructions, and response options of the WOUND-Q based on feedback from the translation work
26
27 and to harmonize the translations by comparing the Danish and Dutch with each other and with the
28
29 English version.
30
31
32
33
34

35 **Phase II: Quantitative**

36
37 The phase II field-test study begins with a pilot field-test sample to identify any final changes to the
38
39 scales that are needed. Data from the first 250 participants are used to examine the psychometric
40
41 performance of each scale.
42
43

44
45 Phase II involves collection of data from a large international sample of patients with wounds
46
47 from sites in Canada (University of St. Michael's, Toronto), Denmark (Odense University Hospital,
48
49 Odense), The Netherlands (Catharina Hospital, Eindhoven; DaVinci Wound Clinic, Geldrop; Erasmus
50
51 Medical Center, Rotterdam), and the USA (Brigham and Women's Hospital, Boston; Massachusetts
52
53 General Hospital Boston; University of California, Los Angeles Berkley East Nursing Home, Berkley;
54
55
56
57
58
59
60

1
2
3 University of California, Los Angeles Medical Center, Santa Monica; MedStar Georgetown University
4 Hospital, and MedStar Washington Hospital Center, Washington). Additional sites can be added if
5
6 needed to ensure that the sample is large enough to explore how the items and scales function at the
7
8 subgroup level.
9
10

11
12 Participants are aged 18 years and older, cognitively able to self-report, and have one or more
13
14 chronic wounds anywhere on their body. A chronic wound is defined as a wound that has lasted 3
15
16 months or longer. Patients are recruited in hospital clinics by research assistants who obtain informed
17
18 consent. Data are collected using tablets with data entered into databases. REDCap databases are hosted
19
20 at Brigham and Women's Hospital in Boston (for the Canadian and USA data), and at Odense
21
22 University Hospital (for Danish data). In the Netherlands, data are collected using the Castor database.
23
24 Instructions with branching logic are used to ensure that only correct scales are administered to reduce
25
26 respondent burden.
27
28
29

30
31 Data collected via separate databases are merged using IBM SPSS Statistics V.25 and are
32
33 formatted appropriately for RUMM2030 software for RMT analysis [54]. The RMT analysis is used to
34
35 refine each scale and to create the scoring algorithms that future users of the scales will use. A range of
36
37 evidence is used to evaluate each item in a scale and examine how the items function as a set. Items that
38
39 are the most effective in measuring the concepts measured by a scale are retained. Items that do not
40
41 perform well are removed. Decisions are based on the following set of statistical and graphical tests are
42
43 used, and described in detail elsewhere [30]:
44
45

46
47 *Thresholds for item response options:* We examine thresholds between response options (eg, “not at all”
48
49 and “a little”) to determine if a scales response categories are ordered, meaning that a “1” on a 4-point
50
51 scale sits lower down a continuum than a “2,” etc. Items with disordered thresholds may be dropped or
52
53 recoded to ensure thresholds are properly ordered.
54
55
56
57
58
59
60

1
2
3 *Item fit statistics:* Three fit indicators are inspected including log residuals (item–person interaction),
4
5 Chi-square values (item–trait interaction), and item characteristic curves. As a guide, ideal fit residuals
6
7 are between -2.5 and $+2.5$, with Bonferroni adjusted Chi-square values non-significant. The three fit
8
9 indicators are interpreted together to decide items to retain or drop.
10

11
12 *Dependency:* Residual correlations between pairs of items are inspected to identify high residual
13
14 correlations as these can inflate reliability. For high residual correlations, a subtest is performed to
15
16 determine the impact on the reliability statistic (Person Separation Index).
17

18
19 *Targeting:* The location of items is examined to determine if they are evenly spread over a reasonable
20
21 range that matches the range of the construct reported by the sample. There should be minimal evidence
22
23 of a floor or ceiling effect so that people with a wide variety of wounds at different stages of healing can
24
25 be effectively measured over time.
26

27
28 *Differential item functioning (DIF):* DIF is examined using ANOVA of item residuals to determine if
29
30 individuals in subgroups (e.g., sex, age, country, type of wound) respond differently to items despite the
31
32 same measured trait level. We choose random samples to create equal-sized subgroups. Items with Chi-
33
34 square values significant after Bonferroni adjustment are split on the variable that evidences DIF, and
35
36 the new and original person locations are correlated to examine impact on scoring.
37

38
39 *Unidimensionality:* We determine if all items in a scale measure the same, single latent construct using
40
41 the method proposed by Smith based on independent t-tests [55].
42
43

44
45 *Person separation index:* This reliability statistic measures error associated with the measurement of
46
47 people in a sample and is similar in interpretation to Cronbach α [56].
48

49
50 The minimum number of people needed to perform RMT analysis is 150 to have 50 respondents
51
52 in each of 3 class intervals for the Chi-square analysis for tests of item fit [57]. To examine DIF by
53
54
55
56
57
58
59
60

country will require 600 participants ($n=150$ per country). Our target is 250 per country to provide an even more robust scoring algorithms and normative scores.

In IBM SPSS Statistics V.25, traditional psychometric properties are examined including reliability (internal consistency), test-retest reproducibility (assessed 7 days after the initial completion), and construct validity. Once item reduction and psychometric validation of the field-test data is completed, the WOUND-Q will be made available for licensing through the Q-Portfolio website (www.qportfolio.org).

Subsequent phases

We plan to seek grant funding to conduct a phase III study to examine further measurement properties on the item-reduced scales, such as concurrent validity (the degree to which scores on an instrument correlate with the Wound-QoL [27]), and to determine each scales' ability to measure clinical change following wound treatment using anchor-based and distribution-based methods [58-60]. These studies will be planned to reflect priorities identified by wound care teams and will utilize our international network of wound care centres.

Patient and public involvement

Our approach to PROM development is patient-oriented as we engage a large sample of people with wounds as well as clinical experts, in all stages of our research. Input from patients with chronic wounds are indispensable to ensuring that the scales are developed to measure outcomes that matter to patients in the language they use so that the final instrument resonates. Patients who take part in qualitative interviews are invited to participate in the cognitive interviews as continuity of involvement ensures the scales accurately reflect the experiences of patients living with chronic wounds. Involvement of experts in the research team meeting half way through the qualitative interview phases, as well as during scale

1
2
3 refinement phase. Involvement of experts ensures that the scales will cover all clinically relevant
4
5 outcomes and experiences of care.
6

7 8 **ETHICS**

9
10 This study is coordinated at Brigham and Women's Hospital (Boston, USA). Ethics board approval was
11
12 obtained from sites in Canada (University of St. Michael's, Toronto), The Netherlands (Catharina
13
14 Hospital, Eindhoven; DaVinci Wound Clinic, Geldrop; Erasmus Medical Center, Rotterdam), and the
15
16 USA (Brigham and Women's Hospital, University of California, Los Angeles Berkley East Nursing
17
18 Home, and University of California, Los Angeles Medical Center, MedStar Georgetown University
19
20 Hospital, and MedStar Washington Hospital Center). For Odense University Hospital in Denmark, we
21
22 obtained permission at the data protecting agency since ethics is not required for studies that involve
23
24 questionnaire surveys in Denmark.
25
26

27
28 Participants provide both written and oral consent before participating in an interview, and
29
30 written consent for participating in the field-test study. Participants in phase I are asked to discuss issues
31
32 that can be sensitive, and they may experience distress. If necessary, we put participants in touch with a
33
34 healthcare provider at the recruiting site to obtain support. Participant data is de-identified during
35
36 transcription for the qualitative interviews. All data collected is kept secure and confidential following
37
38 institution rules governing research data storage.
39
40

41 42 **DISSEMINATION**

43
44 The WOUND-Q will be made available free of charge to all non-profit users. Our team will promote
45
46 uptake of the WOUND-Q among stakeholder groups including researchers, healthcare practitioners,
47
48 decision-makers, and policy-makers. Our dissemination initiatives will include face-to-face interactions
49
50 such as presentations at national and international meetings, as well as electronic and hard-copy media,
51
52 including publication in journals that are valued and read by our target audiences. The Q-Portfolio
53
54
55
56
57
58
59
60

1
2
3 website (www.qportfolio.org) and social media (e.g., Twitter, Instagram) will be used to spread
4 awareness of the WOUND-Q to our network of followers.
5
6
7
8
9

10 **FIGURE CAPTIONS**

11
12
13
14
15 Figure 1: Flow diagram illustrating the multiphase mixed methods approach to the development of the
16 WOUND-Q. QUAN, quantitative study component; QUAL, qualitative study component. Image
17 reproduced from Wong Riff et al
18
19
20
21
22
23

24 Figure 2: Translation and cultural adaption steps for the WOUND-Q. Image reproduced from Van
25 Alphen et al
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Martinengo L, Olsson M, Bajpai R, *et al*. Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies. *Ann Epidemiol* 2019;29:8–15. doi:[10.1016/j.annepidem.2018.10.005](https://doi.org/10.1016/j.annepidem.2018.10.005)
2. Nussbaum SR, Carter MJ, Fife CE, *et al*. An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. *Value Health* 2018;21:27–32. doi:[10.1016/j.jval.2017.07.007](https://doi.org/10.1016/j.jval.2017.07.007)
3. Guest JF, Ayoub N, McIlwraith T, *et al*. Health economic burden that wounds impose on the National Health Service in the UK. *BMJ Open* 2015;5:e009283. doi:[10.1136/bmjopen-2015-009283](https://doi.org/10.1136/bmjopen-2015-009283)
4. <https://wounds.cochrane.org/>. (Accessed May 2019).
5. Smith F, Dryburgh N, Donaldson J, *et al*. Debridement for surgical wounds. *Cochrane Database Syst Rev* 2013;9:CD006214. doi:[10.1002/14651858.CD006214.pub4](https://doi.org/10.1002/14651858.CD006214.pub4)
6. Kranke P, Bennett MH, Martyn-St James M, *et al*. Hyperbaric oxygen therapy for chronic wounds. *Cochrane Database Syst Rev* 2015;6:CD004123. doi:[10.1002/14651858.CD004123.pub4](https://doi.org/10.1002/14651858.CD004123.pub4)
7. Norman G, Westby MJ, Rithalia AD, *et al*. Dressings and topical agents for treating venous leg ulcers. *Cochrane Database Syst Rev* 2018;6:CD012583. doi:[10.1002/14651858.CD012583.pub2](https://doi.org/10.1002/14651858.CD012583.pub2)
8. Dumville JC, Webster J, Evans D, *et al*. Negative pressure wound therapy for treating pressure ulcers. *Cochrane Database Syst Rev* 2015;5:CD011334. doi:[10.1002/14651858.CD011334.pub2](https://doi.org/10.1002/14651858.CD011334.pub2)
9. Calvert M, Kyte D, Price G, *et al*. Maximising the impact of patient reported outcome assessment for patients and society. *BMJ* 2019;364:k5267. doi:[10.1136/bmj.k5267](https://doi.org/10.1136/bmj.k5267)
10. Nelson EC, Eftimovska E, Lind C, *et al*. Patient reported outcome measures in practice. *BMJ* 2015;350:g7818. doi:[10.1136/bmj.g7818](https://doi.org/10.1136/bmj.g7818)
11. Black N. Patient reported outcome measures could help transform healthcare. *BMJ* 2013;346:f167. doi:[10.1136/bmj.f167](https://doi.org/10.1136/bmj.f167)
12. Poku E, Aber A, Phillips P, *et al*. Systematic review assessing the measurement properties of patient-reported outcomes for venous leg ulcers. *BJS Open* 2017;1:138–47. doi:[10.1002/bjs5.25](https://doi.org/10.1002/bjs5.25)
13. Gorecki C, Nixon J, Lamping DL, *et al*. Patient-reported outcome measures for chronic wounds with particular reference to pressure ulcer research: a systematic review. *Int J Nurs Stud* 2014;51:157–65. doi:[10.1016/j.ijnurstu.2013.03.004](https://doi.org/10.1016/j.ijnurstu.2013.03.004)
14. González-Consuegra RV, Verdú J. Quality of life in people with venous leg ulcers: an integrative review. *J Adv Nurs* 2011;67:926–44. doi:[10.1111/j.1365-2648.2010.05568.x](https://doi.org/10.1111/j.1365-2648.2010.05568.x)
15. Palfreyman SJ, Tod AM, Brazier JE, *et al*. A systematic review of health-related quality of life instruments used for people with venous ulcers: an assessment of their suitability and psychometric properties. *J Clin Nurs* 2010;19:2673–703. doi:[10.1111/j.1365-2702.2010.03269.x](https://doi.org/10.1111/j.1365-2702.2010.03269.x)
16. Hyland ME, Ley A, Thomson B. Quality of life of leg ulcer patients: questionnaire and preliminary findings. *J Wound Care* 1994;3:294–8. doi:[10.12968/jowc.1994.3.6.294](https://doi.org/10.12968/jowc.1994.3.6.294)

17. Hareendran A, Doll H, Wild DJ, *et al*. The venous leg ulcer quality of life (VLU-QoL) questionnaire: development and psychometric validation. *Wound Repair Regen* 2007;**15**:465–73. doi:[10.1111/j.1524-475X.2007.00253.x](https://doi.org/10.1111/j.1524-475X.2007.00253.x)
18. Smith JJ, Guest MG, Greenhalgh RM, *et al*. Measuring the quality of life in patients with venous ulcers. *J Vasc Surg* 2000;**31**:642–9. doi:[10.1067/mva.2000.104103](https://doi.org/10.1067/mva.2000.104103)
19. Pilot study investigating the feasibility of an ulcer-specific quality of life questionnaire. *Phlebology* 2005;**20**:14–27. doi:[10.1258/0268355053300839](https://doi.org/10.1258/0268355053300839)
20. Palfreyman S, Michaels J, Brazier J. Development of a tool to examine the effect of venous ulcers on patients' quality of life. *Nurs Stand* 2007;**21**:57–8. doi:[10.7748/ns2007.07.21.45.57.c4585](https://doi.org/10.7748/ns2007.07.21.45.57.c4585)
21. Bland JM, Dumville JC, Ashby RL, *et al*. Validation of the VEINES-QOL quality of life instrument in venous leg ulcers: repeatability and validity study embedded in a randomised clinical trial. *BMC Cardiovasc Disord* 2015;**15**:85. doi:[10.1186/s12872-015-0080-7](https://doi.org/10.1186/s12872-015-0080-7)
22. Brown A, Kendall S, Flanagan M, *et al*. Encouraging patients to self-care - the preliminary development and validation of the VeLUSET©, a self-efficacy tool for venous leg ulcer patients, aged 60 years and over. *Int Wound J* 2014;**11**:326–34. doi:[10.1111/iwj.12199](https://doi.org/10.1111/iwj.12199)
23. Abetz L, Sutton M, Brady L, *et al*. The Diabetic Foot Ulcer Scale (DFS): a quality of life instrument for use in clinical trials. *Practical Diabetes Int* 2002;**19**:167–75. doi:[10.1002/pdi.356](https://doi.org/10.1002/pdi.356)
24. Vileikyte L, Peyrot M, Bundy C, *et al*. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. *Diabetes Care* 2003;**26**:2549–55. doi:[10.2337/diacare.26.9.2549](https://doi.org/10.2337/diacare.26.9.2549)
25. Gorecki C, Brown JM, Cano S, *et al*. Development and validation of a new patient-reported outcome measure for patients with pressure ulcers: the PU-QOL instrument. *Health Qual Life Outcomes* 2013;**11**:95. doi:[10.1186/1477-7525-11-95](https://doi.org/10.1186/1477-7525-11-95)
26. Kisala PA, Tulsy DS, Choi SW, *et al*. Development and psychometric characteristics of the SCI-QOL Pressure Ulcers scale and short form. *J Spinal Cord Med* 2015;**38**:303–14. doi:[10.1179/2045772315Y.0000000017](https://doi.org/10.1179/2045772315Y.0000000017)
27. Price P, Harding K. Cardiff Wound Impact Schedule: the development of a condition-specific questionnaire to assess health-related quality of life in patients with chronic wounds of the lower limb. *Int Wound J* 2004;**1**:10–7. doi:[10.1111/j.1742-481x.2004.00007.x](https://doi.org/10.1111/j.1742-481x.2004.00007.x)
28. Blome C, Baade K, Debus ES, *et al*. The “Wound-QoL”: A short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. *Wound Repair Regen* 2014;**22**:504–14. doi:[10.1111/wrr.12193](https://doi.org/10.1111/wrr.12193)
29. Petrillo J, Cano SJ, McLeod LD, *et al*. Using classical test theory, item response theory, and Rasch measurement theory to evaluate patient-reported outcome measures: a comparison of worked examples. *Value Health* 2015;**18**:25–34. doi:[10.1016/j.jval.2014.10.005](https://doi.org/10.1016/j.jval.2014.10.005)
30. Hobart J, Cano S. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. *Health Technol Assess* 2009;**13**:iii, ix–x, 1–177. doi:[10.3310/hta13120](https://doi.org/10.3310/hta13120)

31. Sierakowski K, Dean NR, Pusic AL, *et al.* International multiphase mixed methods study protocol to develop a cross-cultural patient-reported outcome and experience measure for hand conditions (HAND-Q). *BMJ Open* 2019;**9**:e025822. doi:[10.1136/bmjopen-2018-025822](https://doi.org/10.1136/bmjopen-2018-025822)
32. Klassen AF, Kaur M, Johnson N, *et al.* International phase I study protocol to develop a patient-reported outcome measure for adolescents and adults receiving gender-affirming treatments (the GENDER-Q). *BMJ Open* 2018;**8**:e025435. doi:[10.1136/bmjopen-2018-025435](https://doi.org/10.1136/bmjopen-2018-025435)
33. Wong Riff K W Y, Tsangaris E, Goodacre T, *et al.* International multiphase mixed methods study protocol to develop a cross-cultural patient-reported outcome instrument for children and young adults with cleft lip and/or palate (CLEFT-Q). *BMJ Open* 2017;**7**:e015467. doi:[10.1136/bmjopen-2016-015467](https://doi.org/10.1136/bmjopen-2016-015467)
34. Aaronson N, Alonso J, Burnam A, *et al.* Assessing health status and quality-of-life instruments: attributes and review criteria. *Qual Life Res* 2002;**11**:193–205.
35. US Department of Health and Human Services. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available at: <https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf> (accessed May 2019).
36. Patrick DL, Burke LB, Gwaltney CJ, *et al.* Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. *Value Health* 2011;**14**:967–77. doi:[10.1016/j.jval.2011.06.014](https://doi.org/10.1016/j.jval.2011.06.014)
37. Patrick DL, Burke LB, Gwaltney CJ, *et al.* Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. *Value Health* 2011;**14**:978–88. doi:[10.1016/j.jval.2011.06.013](https://doi.org/10.1016/j.jval.2011.06.013)
38. Wild D, Grove A, Martin M, *et al.* Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. *Value Health* 2005;**8**:94–104. doi:[10.1111/j.1524-4733.2005.04054.x](https://doi.org/10.1111/j.1524-4733.2005.04054.x)
39. Reeve BB, Wyrwich KW, Wu AW, *et al.* ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. *Qual Life Res* 2013;**22**:1889–905. doi:[10.1007/s11136-012-0344-y](https://doi.org/10.1007/s11136-012-0344-y)
40. Mokkink LB, Terwee CB, Patrick DL, *et al.* The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. *Qual Life Res* 2010;**19**:539–49. doi:[10.1007/s11136-010-9606-8](https://doi.org/10.1007/s11136-010-9606-8)
41. Terwee CB, Prinsen C a. C, Chiarotto A, *et al.* COSMIN methodology for evaluating the content validity of patient-reported outcomes measures: a Delphi study. *Qual Life Res* 2018;**27**:1159–70. doi:[10.1007/s11136-018-1829-0](https://doi.org/10.1007/s11136-018-1829-0)
42. Thorne S, Kirkham SR, MacDonald-Emes J. Interpretive description: A noncategorical qualitative alternative for developing nursing knowledge. *Res Nurs Health* 1997;**20**:169–77. doi:[10.1002/\(SICI\)1098-240X\(199704\)20:2<169::AID-NUR9>3.0.CO;2-I](https://doi.org/10.1002/(SICI)1098-240X(199704)20:2<169::AID-NUR9>3.0.CO;2-I)

- 1
2
3 43. Thorne SE. Interpretive description. Developing qualitative inquiry, vol 2. Walnut Creek (CA): Left
4 Coast Press, 2008.
5
6 44. Given LM, Sandelowski M. Theoretical Saturation. In: Given LM, ed. The SAGE Encyclopedia of
7 Qualitative Research Methods. Thousand Oaks: SAGE Publications, Inc. 2008. 876–876.
8 doi:[10.4135/9781412963909](https://doi.org/10.4135/9781412963909)
9
10 45. Rasch G. Studies in mathematical psychology: 1. Probabilistic Models for Some Intelligence and
11 Attainment Tests. Copenhagen: Danmarks pædagogiske Institut. 1960.
12
13 46. Khadka J, Gothwal VK, McAlinden C, *et al*. The importance of rating scales in measuring patient-
14 reported outcomes. *Health Qual Life Outcomes* 2012;**10**:80. doi:[10.1186/1477-7525-10-80](https://doi.org/10.1186/1477-7525-10-80)
15
16 47. Willis GB. Cognitive interviewing: A tool for improving questionnaire design. Thousand Oaks, CA:
17 Sage Publications 2005.
18
19 48. Collins D. Pretesting survey instruments: An overview of cognitive methods. *Qual Life Res*
20 2003;**12**:229–38. doi:[10.1023/A:1023254226592](https://doi.org/10.1023/A:1023254226592)
21
22 49. Van Someren M, Barnard Y, Sandberg J. The think-aloud method. London: Academic Press; 1994.
23
24 50. Harris PA, Taylor R, Thielke R, *et al*. Research electronic data capture (REDCap)--a metadata-
25 driven methodology and workflow process for providing translational research informatics support. *J*
26 *Biomed Inform* 2009;**42**:377–81. doi:[10.1016/j.jbi.2008.08.010](https://doi.org/10.1016/j.jbi.2008.08.010)
27
28 51. Van Alphen TC, Poulsen L, van Haren ELWG, *et al*. Danish and Dutch linguistic validation and
29 cultural adaptation of the WOUND-Q, a PROM for chronic wounds. *Eur J Plast Surg* 2019;1-10.
30 doi:[10.1007/s00238-019-01529-7](https://doi.org/10.1007/s00238-019-01529-7)
31
32 52. WHO (World Health Organization). The process of translation and adaptation of instruments.
33 Available at: http://www.who.int/substance_abuse/research_tools/translation/en/ (accessed May
34 2019)
35
36 53. Poulsen L, Rose M, Klassen A, *et al*. Danish translation and linguistic validation of the BODY-Q: a
37 description of the process. *Eur J Plast Surg* 2017;**40**:29–38. doi:[10.1007/s00238-016-1247-x](https://doi.org/10.1007/s00238-016-1247-x)
38
39 54. RUMM Lab. <http://www.rummlab.com.au/> (accessed 29 May 2019).
40
41 55. Smith EV. Detecting and evaluating the impact of multidimensionality using item fit statistics and
42 principal component analysis of residuals. *J Appl Meas* 2002;**3**:205–31.
43
44 56. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill, 1994.
45
46 57. Sample Size and Item Calibration or Person Measure Stability. Available at:
47 <http://www.rasch.org/rmt/rmt74m.htm> (accessed May 2019)
48
49 58. Terwee CB, Dekker FW, Wiersinga WM, *et al*. On assessing responsiveness of health-related
50 quality of life instruments: guidelines for instrument evaluation. *Qual Life Res* 2003;**12**:349–62. doi:
51 [10.1023/A:1023499322593](https://doi.org/10.1023/A:1023499322593)
52
53 59. Husted JA, Cook RJ, Farewell VT, *et al*. Methods for assessing responsiveness: a critical review and
54 recommendations. *J Clin Epidemiol* 2000;**53**:459–68. doi: [10.1016/S0895-4356\(99\)00206-1](https://doi.org/10.1016/S0895-4356(99)00206-1)
55
56 60. Brozek JL, Guyatt GH, Schünemann HJ. How a well-grounded minimal important difference can
57 enhance transparency of labelling claims and improve interpretation of a patient reported outcome
58 measure. *Health Qual Life Outcomes* 2006;**4**:69. doi:[10.1186/1477-7525-4-69](https://doi.org/10.1186/1477-7525-4-69)
59
60

Table 1: WOUND-Q interview guide**Wound**

1. How did your wound originate? Probe: any comorbid diabetes, obesity
2. Can you tell me about any wounds you've had in the past?
3. How was the healing process for you? Probe: hemostasis, inflammation, proliferation, and remodeling

Treatments

4. What treatment(s) have you had for your wound?
5. What was good/bad about the treatment(s)? Probe: side effects

Symptoms

6. Can you describe any symptoms you experience? Probe: e.g., pain, odor, exudate
7. Have symptoms changed over time? Probe: hemostasis, inflammation, proliferation, and remodeling
8. How bothersome are the symptoms?
9. How do you cope with the symptoms?

Recovery

10. How quickly did you recover?
11. What was the recovery process like? Probe: hemostasis, inflammation, proliferation, and re-modelling
12. Can you describe the early life impact? Probe: impact on physical, social, emotional, social life

Appearance

13. How would you describe the appearance of your wound? Probe for descriptive detail.
14. What do you like/dislike about the appearance of your wound?
15. How has your appearance changed? Probe hemostasis, inflammation, proliferation, and remodeling
16. Is there anything about the wound you wish looked different? Probe for descriptive detail.
17. Do/did you ever hide or cover your wound? How do you do this?

Physical Function

18. Does the wound create physical issues? Probe: e.g., mobility, activity limitations
19. How have these physical issues changed? Probe hemostasis, inflammation, proliferation, remodeling

Psychological Wellbeing

20. How does your wound affect how you feel? Probe: happy, sad, anxious, frustrated, self-conscious.
21. How does your wound affect how you feel about yourself? Probe: self-esteem; body image; confidence.
22. How have your emotions changed? Probe hemostasis, inflammation, proliferation, remodeling

Social Life


23. What has it been like for you at home? Probe: partner, family, children.
24. Has the wound affected your usual activities? Probe: work/education?
25. Do people ever comment on your wound? Probe: how did you react; how did you feel?
26. Are there things you would have liked to do but don't because of your wound?
27. Has anyone ever treated you differently because of your wound? Probe: friends, family, strangers.
28. How else does your wound affect your social life? Probe: with friends, meeting new people, dating.

Experience of Care


29. Who did you see at the hospital or clinic? Probe: doctor, nurse, receptionist, etc.
30. What are the people like who cared for you? Probe: friendly; made you feel comfortable; easy to talk to; listened to you; respectful; available.
31. What kind of verbal and written information did you receive? Probe: gave enough information; let you ask questions; answered your questions; information about recovery; treatment information
32. What things could the healthcare team do differently to improve the care you received?
33. What should the perfect wound healing center be like?

Other Questions

34. Is there anything I have not asked you that you think it is important for me to know?



Translation and cultural adaption steps for the WOUND-Q. Image reproduced from Van Alphen et al [60]



Flow diagram illustrating the multiphase mixed methods approach to the development of the WOUND-Q. QUAN, quantitative study component; QUAL, qualitative study component. Image reproduced from Wong Riff et al [33]

78x108mm (300 x 300 DPI)

BMJ Open

International Mixed Methods Study Protocol to Develop a Patient-Reported Outcome Measure for all Types of Chronic Wounds (the WOUND-Q)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-032332.R2
Article Type:	Protocol
Date Submitted by the Author:	03-Jan-2020
Complete List of Authors:	Klassen, Anne; McMaster University, Pediatrics van Haren, Emiel; Catharina Ziekenhuis, Plastic and Reconstructive Surgery, Cross, Karen; St Michael's Hospital, Plastic Surgery Fan, Kenneth; MedStar Georgetown University Hospital, Plastic and Reconstructive Surgery Gibbons, Chris; Harvard Medical School, Faculty of Medicine Hoogbergen, Maarten; Catharina Ziekenhuis Longmire, Natasha; McMaster University Poulsen, Lotte; University of Southern Denmark Sorensen, Jens; Odense University Hospital Squitieri, Lee; University of Southern California Tsangaris, Elena; Brigham and Women's Hospital van Alphen, Tert; Catharina Ziekenhuis van Dishoeck, Anne-Margreet; Erasmus Medical Center, Plastic and Reconstructive Surgery Vasilic, Dali; Erasmus Medical Center, Plastic Surgery Pusic, Andrea; Brigham and Women's Hospital Biomedical Research Institute
Primary Subject Heading:	Surgery
Secondary Subject Heading:	Qualitative research, Health services research
Keywords:	patient-reported outcome, quality of life, psychometrics, Rasch, WOUND MANAGEMENT, PLASTIC & RECONSTRUCTIVE SURGERY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Title:** International Mixed Methods Study Protocol to Develop a Patient-Reported Outcome Measure for
4 all Types of Chronic Wounds (the WOUND-Q)
5
6
7

8
9 **Authors:**
10

- 11
12 1. Anne F. Klassen DPhil, Department of Pediatrics, McMaster University, 3N27, 1280 Main Street W,
13
14 Hamilton, ON, Canada
- 15
16 2. Emiel LWG van Haren MD, Department of Plastic and Reconstructive Surgery, Catharina
17
18 Ziekenhuis, Eindhoven, the Netherlands
- 19
20 3. Karen Cross MD PhD, Department of Plastic Surgery, St. Michael's Hospital and Keenan Research
21
22 Centre, Toronto, Ontario, Canada
- 23
24 4. Kenneth L Fan MD, Department of Plastic and Reconstructive Surgery, MedStar Georgetown
25
26 University Hospital, Washington, DC, USA
- 27
28 5. Chris Gibbons PhD, Department of Surgery, Brigham and Women's Hospital, 75 Francis S, Boston,
29
30 MA, USA
- 31
32 6. Maarten M Hoogbergen MD PhD, Department of Plastic and Reconstructive Surgery, Catharina
33
34 Ziekenhuis, Eindhoven, the Netherlands
- 35
36 7. Natasha Longmire MSc, Department of Psychology, University of Toronto, Toronto, ON, Canada
- 37
38 8. Lotte Poulsen MD, Department of Plastic and Reconstructive Surgery, University of Southern
39
40 Denmark, Odense, Denmark
- 41
42 9. Jens Ahm Sørensen MD PhD, Department of Plastic and Reconstructive Surgery, Odense University
43
44 Hospital, Odense, Denmark
- 45
46 10. Lee Squitieri MD, PhD, MS, Division of Plastic and Reconstructive Surgery, University of Southern
47
48 California, Los Angeles, CA, USA
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 11. Elena Tsangaris PhD, Department of Surgery, Brigham and Women's Hospital, 75 Francis St,
4
5 Boston, MA, USA
6

7
8 12. Tert C van Alphen MD, MBA, Department of Plastic and Reconstructive Surgery, Catharina
9
10 Ziekenhuis, Eindhoven, The Netherlands
11

12
13 13. Anne-Margreet van Dishoeck PhD, Department of Plastic and Reconstructive Surgery, Erasmus
14
15 Medical Center, Rotterdam, The Netherlands
16

17
18 14. Dali Vasilic MD, PhD, Department of Plastic and Reconstructive Surgery, Erasmus Medical Center,
19
20 Rotterdam, The Netherlands
21

22
23 15. Andrea L Pusic MD MSc, Department of Surgery, Brigham and Women's Hospital, 75 Francis S,
24
25 Boston, MA, USA
26

27
28 **Corresponding Author:** Andrea Pusic MD MSc, Department of Surgery Brigham and Women's
29
30 Hospital, 75 Francis S, Boston, MA, USA, 02116, apusic@bwh.harvard.edu
31

32
33 **Funding Statement:** Phases I and II of this study are funded by research grants received from the
34
35 Plastic Surgery Foundation (120593). The authors have no financial interest to declare in relation to the
36
37 content of this article. The Article Processing Charge was paid from the Plastic Surgery Foundation
38
39 grant.
40
41

42
43 **Contributions:** AFK, ALP conceived and designed the study. AFK, ELWGvH, KC, KLF, CG, MMH,
44
45 NL, LP, JS, LS, ET, TCvA, AvD, DV, ALP revised the article critically for important intellectual
46
47 content and have approved the final version to be published.
48
49

50
51 **Competing Interests Statement:** The WOUND-Q will be owned by Memorial Sloan-Kettering Cancer
52
53 Center. Drs. Pusic and Klassen are co-developers of other Q-Portfolio instruments and receive a share of
54
55

1
2
3 any license revenue on the inventor sharing policies of the institutions that own them. The remaining
4
5 authors have no conflict of interest to declare. **Word count = (maximum 4000)**
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

ABSTRACT = 270 of 300

Introduction: Most patient-reported outcome measures (PROM) for chronic wounds are specific to a single wound type (e.g., pressure ulcer) or part of the body. A barrier to outcome assessment in wound care and research is the lack of a rigorously-designed PROM that can be used across wound types and locations. This mixed method study describes the protocol for an international collaboration to develop and validate a new PROM called the WOUND-Q.

Methods and analysis: In phase 1, the qualitative approach of interpretive description is used to elicit concepts important to people with wounds regarding outcome. Participants from Canada, Denmark, the Netherlands, and the USA are aged 18 years and older and have a wound that has lasted 3 months or longer. Interviews are digitally recorded, transcribed and coded. A conceptual framework and preliminary item pool are developed from the qualitative dataset. Draft scales are formed to cover important themes in the conceptual framework. These scales are refined using feedback from people with chronic wounds and wound care experts. After refinement, the scales are translated into Danish and Dutch following rigorous methods to prepare for the international field-test study. In phase II, data are collected in Canada, Denmark, the Netherlands, and the USA. An international sample of people with a large variety of chronic wounds complete the WOUND-Q. Rasch Measurement Theory analysis is used to identify the best subset of items to retain for each scale and to examine reliability and validity.

Ethics and dissemination: This study is coordinated at Brigham and Women's Hospital (Boston, USA). Ethics board approval was received at each participating site for both study phases. Findings will be published in peer-reviewed journals and presented at national and international conferences and meetings.

Strengths and limitations of this study

- Recruitment of an international sample makes it possible to develop a patient-reported outcome measure (PROM) that reflects the concerns of patients in multiple countries.
- Including people with varying types of chronic wounds in different locations on the body ensures that the WOUND-Q is broadly applicable.
- We adhere to published guidelines for PROM development, including rigorous methods for translation and cultural adaptation.
- We use a modern psychometric approach (Rasch Measurement Theory) to enhance the interpretability of WOUND-Q scores.
- A limitation of our study is that patient involvement does not include membership in the research team. Another limitation is that the WOUND-Q field-test takes place only in high income countries.

INTRODUCTION

Each year, millions of individuals require treatment for chronic wounds. A recent systematic review of 11 studies reported a prevalence in the general population to be 2.21 and 1.51 per 1000 population for wounds of mixed etiology and chronic leg ulcers respectively [1]. Wound care has a huge economic impact on healthcare systems worldwide. An analysis of US Medicare claims for 2014 showed that 15 percent of beneficiaries (8.2 million) had an episode of care for a chronic wound or infection, with costs estimated between 28.1 to 96.8 billion [2]. In the UK, a study estimated that 4 percent of the total expenditure by the NHS in 2012/13 (5.3 billion pounds) went towards managing chronic wounds and associated morbidity for 2.2 million patients [3].

Chronic wounds have many different causes and numerous treatment modalities. The Cochrane Wounds review group, established in 1995, lists more than 150 protocols and reviews of the effects of interventions to prevent and treat wounds and their complications [4]. Outcome measures used in intervention studies tend to involve the use of objective measures (eg, healed wounds, rate of healing, adverse effects). The inclusion of carefully designed patient-reported outcome measures (PROMs) that ask about concerns that matter the most to patients, including bothersome symptoms, such pain, exudate and odor, and the impact of wounds on aspects of quality of life, can provide important additional information from the patient perspective. Cochrane reviews of wound treatments show that such outcomes are often overlooked in treatment studies [e.g., 5-8].

PROMs that measure outcomes that matter to patient, as well as their experience of healthcare, are increasingly used to inform quality improvement initiatives, patient care, and comparative effectiveness research [9-11]. In chronic wounds, four reviews of PROMs have been published [12-15]. These reviews report that generic tools (e.g., SF-36, EQ-5D, Nottingham Health Profile) are often used. Such tools are limited in terms of content validity as they fail to ask about important wound-specific

1
2
3 issues (e.g., odor, exudate). In terms of wound-specific PROMs, most were developed for a specific type
4 of wound, including venous leg ulcers [16-22], foot ulcers [23-24] and pressure ulcers [25-26], or
5 wounds on specific parts of the body [27]. The Wound-QoL [28] represents an exception, as it was
6 designed for all types of chronic wounds. This 17-item instrument, published in 2014, was developed by
7 taking items from three existing PROMs, using factor analysis to determine how the items group
8 together, and then attaching labels (body, everyday life, and psyche) to each concept. The Wound-QoL
9 can be scored separately for each scale or by adding together the scales for a total score.

19 PROMs that add scales together for a total score can be problematic because the concept of
20 interest measured by the instrument may not be clear. The same is true for PROMs that score each scale
21 separately if the scales are composed of item sets that ask about multiple concepts of interest. For
22 example, the body scale from the Wound-QoL has five items that measures a range of concepts,
23 including pain, wound discharge and problems sleeping [28]. Item sets that ask about multiple concepts
24 are limited in their ability to measure change in specific issues. In the context of a clinical trial, such
25 scales can mask effects of treatment (e.g., when the direction and size of the scores vary by concept).
26 The alternative approach is to design a set of independently functioning scales that each measure a
27 unidimensional construct, e.g., discharge, smell, sleep interference, etc. An advantage of this approach is
28 that respondent burden can be decreased as only the scales that are relevant to a particular research
29 question or clinical scenario need to be used.

44 Currently, there is no comprehensive PROM designed using a modern psychometric approach
45 covering all type of chronic wounds located anywhere on the body. The modern psychometric approach
46 uses more sophisticated models and techniques than the traditional approach, providing more diagnostic
47 details that aid in the refinement of scales that have interval (rather than ordinal) measurement properties
48 [29-30]. This protocol describes an international collaboration between investigators in Canada,
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Denmark, the Netherlands, and the USA that aims to develop a new PROM (i.e., the WOUND-Q) for
4 patients with chronic wounds. The WOUND-Q will contain a comprehensive set of independently
5 functioning scales designed to measure outcomes that matter to patients with any type of chronic wound,
6 as well as scales to measure patients experience of wound care. We describe the mixed methods
7 approach that we previously published in the development of other Q-Portfolio instruments [31-33].
8
9
10
11
12
13

14 **METHODS AND ANALYSIS**

15
16 Development of the WOUND-Q follows guidelines for PROM development outlined by the Scientific
17 Advisory Committee of the Medical Outcomes Trust [34], the USA Food and Drug Administration [35],
18 and the International Society for Pharmacoeconomics and Outcomes Research [36-38]. We aim to
19 develop a self-report instrument for adults with any type of chronic wound located anywhere on the
20 body. Our goal is to develop a comprehensive set of independently functioning scales that measure
21 concepts of interest (COI) important to patients and healthcare providers working in chronic wound
22 care.
23
24
25
26
27
28
29
30
31
32

33 Our protocol covers a multi-phase mixed methods study that includes qualitative and quantitative
34 lines of inquiry. Figure 1 shows the three main phases involved in the development of a PROM [33].
35 These phases include iterative steps for item generation, item reduction, and psychometric validation.
36 Careful adherence to the steps outlined in Figure 1 will ensure the WOUND-Q fulfills minimum
37 standards for acceptable psychometric properties described by the International Society for Quality of
38 Life Research (ISOQOL) [39] and the Consensus-based Standards for the Selection of Health Status
39 Measurement Instruments (COSMIN) [40-41].
40
41
42
43
44
45
46
47
48

49 **Phase 1: Qualitative**

1
2
3 We take a qualitative approach called Interpretive Description [42-43]. In our context, this applied
4 health services approach builds upon existing wound-specific theoretical knowledge, clinical
5 knowledge, and scientific research.
6
7
8
9

10 ***Sample***

11
12 Participants are purposively sampled to include a heterogeneous sample that varies by the following
13 characteristics: age (18 years and older), gender, wound type, wound location, phase in the healing
14 process, and risk of poor outcome (smokers and people with comorbid conditions such as diabetes and
15 obesity). Participants are recruited in wound care clinics by a member of the healthcare team who obtain
16 informed consent and pass contact details to a member of the research team to schedule interviews.
17
18
19
20
21
22

23
24 Phase 1 involves sites from Canada (University of St. Michael's College, Toronto), Denmark (Odense
25 University Hospital, Odense), The Netherlands (Catharina Hospital, Eindhoven; DaVinci Wound Clinic,
26 Geldrop), and the USA (University of California, Los Angeles Berkley East Nursing Home, Berkley,
27 and University of California, Los Angeles Medical Center, Santa Monica). Interviews are conducted
28 face-to-face or by phone depending on participant preference and logistics for travel.
29
30
31
32
33
34

35 ***Concept elicitation***

36
37 An interview guide (see Table 1) is used to guide the interviews. Topics are informed by published
38 wound-specific PROMs in the literature [13-15, 25, 28]. Interviews are audio-recorded and transcribed
39 verbatim. Interviews performed in Denmark and the Netherlands are translated into English by
40 professional translators and are coded by the local research team members. Data are coded line-by-line
41 whereby participant quotes are labelled with top level domains, themes, and subthemes. Data are moved
42 from Word to Excel for analysis. Participant characteristics are included in Excel to identify common
43 and unique COI by participant characteristics (e.g., wound type and location). Data analysis is done
44 concurrently with data collection to add new concepts to the interview guide for probing with new
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 participants. Sampling and recruitment continue until the point of saturation is reached, i.e., no further
4
5 new concepts elicited from additional interviews [44].
6

7
8 Rigor in the qualitative phase of the study is ensured by having one team member code the
9
10 qualitative transcripts and a second team member confirm the codes. Also, performing qualitative
11
12 interviews and analysis at the same time makes it possible add COIs important to participants in earlier
13
14 interviews to the interview guide in order to explore if the COIs are important to participants in
15
16 subsequent interviews. Finally, peer debriefing is performed to verify the analysis of the qualitative data
17
18 between members of the team members who perform the coding, as well as with the full research team
19
20 at the research team meeting described below.
21
22

23
24 Qualitative analysis leads to the refinement of a conceptual framework covering the main COI of
25
26 people with chronic wounds. This framework is used to guide scale development.
27

28 ***Item generation***

29
30 Participant quotes are used to create a comprehensive item pool. Items retain the language of
31
32 participants as much as possible to ensure that scale content is easy to understand and resonates with
33
34 patient experience. The item pool is sorted and analyzed by levels of coding (i.e., top level domains,
35
36 theme/subthemes) and participant characteristics (e.g., wound type) to identify common and unique COI
37
38 across. The item pool is used to develop a comprehensive set of independently functioning scales that
39
40 cover key aspects of the conceptual framework.
41
42
43

44 ***Scale development***

45
46 Scale development is informed by the Rasch Measurement Theory (RMT) approach [30, 45]. In this
47
48 approach, a pool of items that are reflective of the underlying constructs are derived from the qualitative
49
50 data to create, for each scale, a conformable set of items that together map out a construct on a clinical
51
52 hierarchy. Later in the study (phase 2), the field-test data are analyzed to see if the theorized construct is
53
54
55
56
57
58
59

1
2
3 supported by the data, i.e., do the data ‘fit’ the Rasch model. The pattern expected by the Rasch model
4 follows a strict deterministic hierarchical ordering of items called Guttman scaling. When the data fit the
5 Rasch model, the estimates derived from the model are considered appropriate, and it is legitimate to
6 sum the items in a scale to obtain a total score that provides interval-level measurement. Scales are
7 assigned appropriate instructions and a time frame for reporting. Each scale is assigned four or five
8 labelled response options to keep them simple and in line with published guidelines [46].
9

16 **Research team meeting**

17
18 After half the interviews are conducted and fully analyzed, a full day face-to-face research team meeting
19 is held to review the sample characteristics and data findings in order to identify and address gaps and
20 issues. At the meeting, wound care experts and the research team reviews codes, the item pool, and
21 drafts scales that cover key aspects of the preliminary conceptual framework. Following this meeting,
22 interviews and analysis continue until no new concepts are elicited from subsequent interviews.
23
24
25
26
27
28
29

30 **Scale refinement**

31
32 Scales are refined through multiple rounds of cognitive interviews [47-48] using the “think aloud”
33 method [49]. The aim is to determine content validity, i.e., whether scale content is relevant,
34 comprehensive, and comprehensible [41]. Participants from the initial interviews are invited to review
35 the scales (English versions). Interviews are audio-recorded, transcribed, and analyzed line-by-line.
36 Feedback on instructions, response options, and items are examined and used to revise the scales.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Between rounds of cognitive interviews, the WOUND-Q is shown to experts for feedback. A
web-based secure Research Electronic Data Capture (REDCap) survey is designed [50]. An
international sample of wound experts are emailed the link to access the survey and provide feedback on

1
2
3 the instructions, response options, and items, and to suggest missing content that could be formed into
4 new items. One reminder email is sent after 10 days. Feedback provided by experts is used to revise the
5
6
7 scales.

10 **Translations**

11
12 The WOUND-Q is translated into Danish and Dutch following steps outlined in Figure 2 [51].

13
14 Translations follow guidelines set forth by the International Society for Pharmacoeconomics and
15 Outcomes Research (ISPOR) [38] and the World Health Organization (WHO) [52]. These guidelines
16
17 outline a rigorous process, previously used by our team [53], which involves two independent forward
18
19 and one backward translation, an expert panel meeting, and a series of cognitive debriefing interviews
20
21 with patients with chronic wounds. The aim is to create conceptually equivalent translations rather than
22
23 literal translations. Producing more than one translation at the same time makes it possible to revise the
24
25 items, instructions, and response options of the WOUND-Q based on feedback from the translation work
26
27 and to harmonize the translations by comparing the Danish and Dutch with each other and with the
28
29 English version.
30
31
32
33
34

35 **Phase II: Quantitative**

36
37 The phase II field-test study begins with a pilot field-test sample to identify any final changes to the
38
39 scales that are needed. Data from the first 250 participants are used to examine the psychometric
40
41 performance of each scale.
42
43

44
45 Phase II involves collection of data from a large international sample of patients with wounds
46
47 from sites in Canada (University of St. Michael's, Toronto), Denmark (Odense University Hospital,
48
49 Odense), The Netherlands (Catharina Hospital, Eindhoven; DaVinci Wound Clinic, Geldrop; Erasmus
50
51 Medical Center, Rotterdam), and the USA (Brigham and Women's Hospital, Boston; Massachusetts
52
53 General Hospital Boston; University of California, Los Angeles Berkley East Nursing Home, Berkley;
54
55
56
57
58
59
60

1
2
3 University of California, Los Angeles Medical Center, Santa Monica; MedStar Georgetown University
4 Hospital, and MedStar Washington Hospital Center, Washington). Additional sites can be added if
5
6 needed to ensure that the sample is large enough to explore how the items and scales function at the
7
8 subgroup level.
9

10
11
12 Participants are aged 18 years and older, cognitively able to self-report, and have one or more
13
14 chronic wounds anywhere on their body. A chronic wound is defined as a wound that has lasted 3
15
16 months or longer. Patients are recruited in hospital clinics by research assistants who obtain informed
17
18 consent. Data are collected using tablets with data entered into databases. REDCap databases are hosted
19
20 at Brigham and Women's Hospital in Boston (for the Canadian and USA data), and at Odense
21
22 University Hospital (for Danish data). In the Netherlands, data are collected using the Castor database.
23
24 Instructions with branching logic are used to ensure that only correct scales are administered to reduce
25
26 respondent burden.
27
28
29

30
31 Data collected via separate databases are merged using IBM SPSS Statistics V.25 and are
32
33 formatted appropriately for RUMM2030 software for RMT analysis [54]. The RMT analysis is used to
34
35 refine each scale and to create the scoring algorithms that future users of the scales will use. A range of
36
37 evidence is used to evaluate each item in a scale and examine how the items function as a set. Items that
38
39 are the most effective in measuring the concepts measured by a scale are retained. Items that do not
40
41 perform well are removed. Decisions are based on the following set of statistical and graphical tests are
42
43 used, and described in detail elsewhere [30]:
44
45

46
47 *Thresholds for item response options:* We examine thresholds between response options (eg, “not at all”
48
49 and “a little”) to determine if a scales response categories are ordered, meaning that a “1” on a 4-point
50
51 scale sits lower down a continuum than a “2,” etc. Items with disordered thresholds may be dropped or
52
53 recoded to ensure thresholds are properly ordered.
54
55
56
57
58
59
60

1
2
3 *Item fit statistics:* Three fit indicators are inspected including log residuals (item–person interaction),
4
5 Chi-square values (item–trait interaction), and item characteristic curves. As a guide, ideal fit residuals
6
7 are between -2.5 and $+2.5$, with Bonferroni adjusted Chi-square values non-significant. The three fit
8
9 indicators are interpreted together to decide items to retain or drop.
10

11
12 *Dependency:* Residual correlations between pairs of items are inspected to identify high residual
13
14 correlations as these can inflate reliability. For high residual correlations, a subtest is performed to
15
16 determine the impact on the reliability statistic (Person Separation Index).
17

18
19 *Targeting:* The location of items is examined to determine if they are evenly spread over a reasonable
20
21 range that matches the range of the construct reported by the sample. There should be minimal evidence
22
23 of a floor or ceiling effect so that people with a wide variety of wounds at different stages of healing can
24
25 be effectively measured over time.
26

27
28 *Differential item functioning (DIF):* DIF is examined using ANOVA of item residuals to determine if
29
30 individuals in subgroups (e.g., sex, age, country, type of wound) respond differently to items despite the
31
32 same measured trait level. We choose random samples to create equal-sized subgroups. Items with Chi-
33
34 square values significant after Bonferroni adjustment are split on the variable that evidences DIF, and
35
36 the new and original person locations are correlated to examine impact on scoring.
37

38
39 *Unidimensionality:* We determine if all items in a scale measure the same, single latent construct using
40
41 the method proposed by Smith based on independent t-tests [55].
42

43
44 *Person separation index:* This reliability statistic measures error associated with the measurement of
45
46 people in a sample and is similar in interpretation to Cronbach α [56].
47

48
49 The minimum number of people needed to perform RMT analysis is 150 to have 50 respondents
50
51 in each of 3 class intervals for the Chi-square analysis for tests of item fit [57]. To examine DIF by
52
53

country will require 600 participants ($n=150$ per country). Our target is 250 per country to provide an even more robust scoring algorithms and normative scores.

In IBM SPSS Statistics V.25, traditional psychometric properties are examined including reliability (internal consistency), test-retest reproducibility (assessed 7 days after the initial completion), and construct validity. Once item reduction and psychometric validation of the field-test data is completed, the WOUND-Q will be made available for licensing through the Q-Portfolio website (www.qportfolio.org).

Subsequent phases

The phase II field-test study is currently ongoing and will be completed in 2020. We plan to seek grant funding to conduct a phase III study to examine further measurement properties on the item-reduced scales, such as concurrent validity (the degree to which scores on an instrument correlate with the Wound-QoL [27]), and to determine each scales' ability to measure clinical change following wound treatment using anchor-based and distribution-based methods [58-60]. These studies will be planned to reflect priorities identified by wound care teams and will utilize our international network of wound care centres.

Patient and public involvement

A limitation of our study is that patient involvement does not include membership in the research team. However, our approach to PROM development is patient-oriented as we engage a large sample of people with wounds as well as clinical experts, in all stages of our research. Input from patients with chronic wounds are indispensable to ensuring that the scales are developed to measure outcomes that matter to patients in the language they use so that the final instrument resonates. Patients who take part in qualitative interviews are invited to participate in the cognitive interviews as continuity of involvement ensures the scales accurately reflect the experiences of patients living with chronic wounds.

1
2
3 We recognize a limitation of using the same participants twice could be that participants not involved in
4 the initial phase may provide new insights. Involvement of experts in the research team meeting half
5 way through the qualitative interview phases, as well as during scale refinement phase. Involvement of
6 experts ensures that the scales will cover all clinically relevant outcomes and experiences of care.
7
8
9
10

11 **ETHICS**

12
13
14 This study is coordinated at Brigham and Women's Hospital (Boston, USA). Ethics board approval was
15 obtained from sites in Canada (University of St. Michael's, Toronto), The Netherlands (Catharina
16 Hospital, Eindhoven; DaVinci Wound Clinic, Geldrop; Erasmus Medical Center, Rotterdam), and the
17 USA (Brigham and Women's Hospital, University of California, Los Angeles Berkley East Nursing
18 Home, and University of California, Los Angeles Medical Center, MedStar Georgetown University
19 Hospital, and MedStar Washington Hospital Center). For Odense University Hospital in Denmark, we
20 obtained permission at the data protecting agency since ethics is not required for studies that involve
21 questionnaire surveys in Denmark.
22
23
24
25
26
27
28
29
30
31

32
33 Participants provide both written and oral consent before participating in an interview, and
34 written consent for participating in the field-test study. Participants in phase I are asked to discuss issues
35 that can be sensitive, and they may experience distress. If necessary, we put participants in touch with a
36 healthcare provider at the recruiting site to obtain support. Participant data is de-identified during
37 transcription for the qualitative interviews. All data collected is kept secure and confidential following
38 institution rules governing research data storage.
39
40
41
42
43
44
45

46 **DISSEMINATION**

47
48
49 The WOUND-Q will be made available free of charge to all non-profit users. Our team will promote
50 uptake of the WOUND-Q among stakeholder groups including researchers, healthcare practitioners,
51 decision-makers, and policy-makers. Our dissemination initiatives will include face-to-face interactions
52
53
54
55
56
57
58
59
60

1
2
3 such as presentations at national and international meetings, as well as electronic and hard-copy media,
4 including publication in journals that are valued and read by our target audiences. The Q-Portfolio
5 website (www.qportfolio.org) and social media (e.g., Twitter, Instagram) will be used to spread
6 awareness of the WOUND-Q to our network of followers.
7
8
9
10
11
12
13

14 **FIGURE CAPTIONS**

15
16
17
18
19 Figure 1: Flow diagram illustrating the multiphase mixed methods approach to the development of the
20 WOUND-Q. QUAN, quantitative study component; QUAL, qualitative study component. Image
21 reproduced from Wong Riff et al
22
23
24
25
26
27

28 Figure 2: Translation and cultural adaption steps for the WOUND-Q. Image reproduced from Van
29 Alphen et al
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Martinengo L, Olsson M, Bajpai R, *et al*. Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies. *Ann Epidemiol* 2019;29:8–15. doi:[10.1016/j.annepidem.2018.10.005](https://doi.org/10.1016/j.annepidem.2018.10.005)
2. Nussbaum SR, Carter MJ, Fife CE, *et al*. An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds. *Value Health* 2018;21:27–32. doi:[10.1016/j.jval.2017.07.007](https://doi.org/10.1016/j.jval.2017.07.007)
3. Guest JF, Ayoub N, McIlwraith T, *et al*. Health economic burden that wounds impose on the National Health Service in the UK. *BMJ Open* 2015;5:e009283. doi:[10.1136/bmjopen-2015-009283](https://doi.org/10.1136/bmjopen-2015-009283)
4. <https://wounds.cochrane.org/>. (Accessed May 2019).
5. Smith F, Dryburgh N, Donaldson J, *et al*. Debridement for surgical wounds. *Cochrane Database Syst Rev* 2013;9:CD006214. doi:[10.1002/14651858.CD006214.pub4](https://doi.org/10.1002/14651858.CD006214.pub4)
6. Kranke P, Bennett MH, Martyn-St James M, *et al*. Hyperbaric oxygen therapy for chronic wounds. *Cochrane Database Syst Rev* 2015;6:CD004123. doi:[10.1002/14651858.CD004123.pub4](https://doi.org/10.1002/14651858.CD004123.pub4)
7. Norman G, Westby MJ, Rithalia AD, *et al*. Dressings and topical agents for treating venous leg ulcers. *Cochrane Database Syst Rev* 2018;6:CD012583. doi:[10.1002/14651858.CD012583.pub2](https://doi.org/10.1002/14651858.CD012583.pub2)
8. Dumville JC, Webster J, Evans D, *et al*. Negative pressure wound therapy for treating pressure ulcers. *Cochrane Database Syst Rev* 2015;5:CD011334. doi:[10.1002/14651858.CD011334.pub2](https://doi.org/10.1002/14651858.CD011334.pub2)
9. Calvert M, Kyte D, Price G, *et al*. Maximising the impact of patient reported outcome assessment for patients and society. *BMJ* 2019;364:k5267. doi:[10.1136/bmj.k5267](https://doi.org/10.1136/bmj.k5267)
10. Nelson EC, Eftimovska E, Lind C, *et al*. Patient reported outcome measures in practice. *BMJ* 2015;350:g7818. doi:[10.1136/bmj.g7818](https://doi.org/10.1136/bmj.g7818)
11. Black N. Patient reported outcome measures could help transform healthcare. *BMJ* 2013;346:f167. doi:[10.1136/bmj.f167](https://doi.org/10.1136/bmj.f167)
12. Poku E, Aber A, Phillips P, *et al*. Systematic review assessing the measurement properties of patient-reported outcomes for venous leg ulcers. *BJS Open* 2017;1:138–47. doi:[10.1002/bjs5.25](https://doi.org/10.1002/bjs5.25)
13. Gorecki C, Nixon J, Lamping DL, *et al*. Patient-reported outcome measures for chronic wounds with particular reference to pressure ulcer research: a systematic review. *Int J Nurs Stud* 2014;51:157–65. doi:[10.1016/j.ijnurstu.2013.03.004](https://doi.org/10.1016/j.ijnurstu.2013.03.004)
14. González-Consuegra RV, Verdú J. Quality of life in people with venous leg ulcers: an integrative review. *J Adv Nurs* 2011;67:926–44. doi:[10.1111/j.1365-2648.2010.05568.x](https://doi.org/10.1111/j.1365-2648.2010.05568.x)
15. Palfreyman SJ, Tod AM, Brazier JE, *et al*. A systematic review of health-related quality of life instruments used for people with venous ulcers: an assessment of their suitability and psychometric properties. *J Clin Nurs* 2010;19:2673–703. doi:[10.1111/j.1365-2702.2010.03269.x](https://doi.org/10.1111/j.1365-2702.2010.03269.x)
16. Hyland ME, Ley A, Thomson B. Quality of life of leg ulcer patients: questionnaire and preliminary findings. *J Wound Care* 1994;3:294–8. doi:[10.12968/jowc.1994.3.6.294](https://doi.org/10.12968/jowc.1994.3.6.294)

17. Hareendran A, Doll H, Wild DJ, *et al*. The venous leg ulcer quality of life (VLU-QoL) questionnaire: development and psychometric validation. *Wound Repair Regen* 2007;**15**:465–73. doi:[10.1111/j.1524-475X.2007.00253.x](https://doi.org/10.1111/j.1524-475X.2007.00253.x)
18. Smith JJ, Guest MG, Greenhalgh RM, *et al*. Measuring the quality of life in patients with venous ulcers. *J Vasc Surg* 2000;**31**:642–9. doi:[10.1067/mva.2000.104103](https://doi.org/10.1067/mva.2000.104103)
19. Pilot study investigating the feasibility of an ulcer-specific quality of life questionnaire. *Phlebology* 2005;**20**:14–27. doi:[10.1258/0268355053300839](https://doi.org/10.1258/0268355053300839)
20. Palfreyman S, Michaels J, Brazier J. Development of a tool to examine the effect of venous ulcers on patients' quality of life. *Nurs Stand* 2007;**21**:57–8. doi:[10.7748/ns2007.07.21.45.57.c4585](https://doi.org/10.7748/ns2007.07.21.45.57.c4585)
21. Bland JM, Dumville JC, Ashby RL, *et al*. Validation of the VEINES-QOL quality of life instrument in venous leg ulcers: repeatability and validity study embedded in a randomised clinical trial. *BMC Cardiovasc Disord* 2015;**15**:85. doi:[10.1186/s12872-015-0080-7](https://doi.org/10.1186/s12872-015-0080-7)
22. Brown A, Kendall S, Flanagan M, *et al*. Encouraging patients to self-care - the preliminary development and validation of the VeLUSET©, a self-efficacy tool for venous leg ulcer patients, aged 60 years and over. *Int Wound J* 2014;**11**:326–34. doi:[10.1111/iwj.12199](https://doi.org/10.1111/iwj.12199)
23. Abetz L, Sutton M, Brady L, *et al*. The Diabetic Foot Ulcer Scale (DFS): a quality of life instrument for use in clinical trials. *Practical Diabetes Int* 2002;**19**:167–75. doi:[10.1002/pdi.356](https://doi.org/10.1002/pdi.356)
24. Vileikyte L, Peyrot M, Bundy C, *et al*. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. *Diabetes Care* 2003;**26**:2549–55. doi:[10.2337/diacare.26.9.2549](https://doi.org/10.2337/diacare.26.9.2549)
25. Gorecki C, Brown JM, Cano S, *et al*. Development and validation of a new patient-reported outcome measure for patients with pressure ulcers: the PU-QOL instrument. *Health Qual Life Outcomes* 2013;**11**:95. doi:[10.1186/1477-7525-11-95](https://doi.org/10.1186/1477-7525-11-95)
26. Kisala PA, Tulsy DS, Choi SW, *et al*. Development and psychometric characteristics of the SCI-QOL Pressure Ulcers scale and short form. *J Spinal Cord Med* 2015;**38**:303–14. doi:[10.1179/2045772315Y.0000000017](https://doi.org/10.1179/2045772315Y.0000000017)
27. Price P, Harding K. Cardiff Wound Impact Schedule: the development of a condition-specific questionnaire to assess health-related quality of life in patients with chronic wounds of the lower limb. *Int Wound J* 2004;**1**:10–7. doi:[10.1111/j.1742-481x.2004.00007.x](https://doi.org/10.1111/j.1742-481x.2004.00007.x)
28. Blome C, Baade K, Debus ES, *et al*. The “Wound-QoL”: A short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. *Wound Repair Regen* 2014;**22**:504–14. doi:[10.1111/wrr.12193](https://doi.org/10.1111/wrr.12193)
29. Petrillo J, Cano SJ, McLeod LD, *et al*. Using classical test theory, item response theory, and Rasch measurement theory to evaluate patient-reported outcome measures: a comparison of worked examples. *Value Health* 2015;**18**:25–34. doi:[10.1016/j.jval.2014.10.005](https://doi.org/10.1016/j.jval.2014.10.005)
30. Hobart J, Cano S. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. *Health Technol Assess* 2009;**13**:iii, ix–x, 1–177. doi:[10.3310/hta13120](https://doi.org/10.3310/hta13120)

31. Sierakowski K, Dean NR, Pusic AL, *et al.* International multiphase mixed methods study protocol to develop a cross-cultural patient-reported outcome and experience measure for hand conditions (HAND-Q). *BMJ Open* 2019;**9**:e025822. doi:[10.1136/bmjopen-2018-025822](https://doi.org/10.1136/bmjopen-2018-025822)
32. Klassen AF, Kaur M, Johnson N, *et al.* International phase I study protocol to develop a patient-reported outcome measure for adolescents and adults receiving gender-affirming treatments (the GENDER-Q). *BMJ Open* 2018;**8**:e025435. doi:[10.1136/bmjopen-2018-025435](https://doi.org/10.1136/bmjopen-2018-025435)
33. Wong Riff K W Y, Tsangaris E, Goodacre T, *et al.* International multiphase mixed methods study protocol to develop a cross-cultural patient-reported outcome instrument for children and young adults with cleft lip and/or palate (CLEFT-Q). *BMJ Open* 2017;**7**:e015467. doi:[10.1136/bmjopen-2016-015467](https://doi.org/10.1136/bmjopen-2016-015467)
34. Aaronson N, Alonso J, Burnam A, *et al.* Assessing health status and quality-of-life instruments: attributes and review criteria. *Qual Life Res* 2002;**11**:193–205.
35. US Department of Health and Human Services. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available at: <https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf> (accessed May 2019).
36. Patrick DL, Burke LB, Gwaltney CJ, *et al.* Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. *Value Health* 2011;**14**:967–77. doi:[10.1016/j.jval.2011.06.014](https://doi.org/10.1016/j.jval.2011.06.014)
37. Patrick DL, Burke LB, Gwaltney CJ, *et al.* Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. *Value Health* 2011;**14**:978–88. doi:[10.1016/j.jval.2011.06.013](https://doi.org/10.1016/j.jval.2011.06.013)
38. Wild D, Grove A, Martin M, *et al.* Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. *Value Health* 2005;**8**:94–104. doi:[10.1111/j.1524-4733.2005.04054.x](https://doi.org/10.1111/j.1524-4733.2005.04054.x)
39. Reeve BB, Wyrwich KW, Wu AW, *et al.* ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. *Qual Life Res* 2013;**22**:1889–905. doi:[10.1007/s11136-012-0344-y](https://doi.org/10.1007/s11136-012-0344-y)
40. Mokkink LB, Terwee CB, Patrick DL, *et al.* The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. *Qual Life Res* 2010;**19**:539–49. doi:[10.1007/s11136-010-9606-8](https://doi.org/10.1007/s11136-010-9606-8)
41. Terwee CB, Prinsen C a. C, Chiarotto A, *et al.* COSMIN methodology for evaluating the content validity of patient-reported outcomes measures: a Delphi study. *Qual Life Res* 2018;**27**:1159–70. doi:[10.1007/s11136-018-1829-0](https://doi.org/10.1007/s11136-018-1829-0)
42. Thorne S, Kirkham SR, MacDonald-Emes J. Interpretive description: A noncategorical qualitative alternative for developing nursing knowledge. *Res Nurs Health* 1997;**20**:169–77. doi:[10.1002/\(SICI\)1098-240X\(199704\)20:2<169::AID-NUR9>3.0.CO;2-I](https://doi.org/10.1002/(SICI)1098-240X(199704)20:2<169::AID-NUR9>3.0.CO;2-I)

- 1
2
3 43. Thorne SE. Interpretive description. Developing qualitative inquiry, vol 2. Walnut Creek (CA): Left
4 Coast Press, 2008.
- 5
6 44. Given LM, Sandelowski M. Theoretical Saturation. In: Given LM, ed. The SAGE Encyclopedia of
7 Qualitative Research Methods. Thousand Oaks: SAGE Publications, Inc. 2008. 876–876.
8 doi:[10.4135/9781412963909](https://doi.org/10.4135/9781412963909)
- 9
10 45. Rasch G. Studies in mathematical psychology: 1. Probabilistic Models for Some Intelligence and
11 Attainment Tests. Copenhagen: Danmarks pædagogiske Institut. 1960.
- 12
13 46. Khadka J, Gothwal VK, McAlinden C, *et al*. The importance of rating scales in measuring patient-
14 reported outcomes. *Health Qual Life Outcomes* 2012;**10**:80. doi:[10.1186/1477-7525-10-80](https://doi.org/10.1186/1477-7525-10-80)
- 15
16 47. Willis GB. Cognitive interviewing: A tool for improving questionnaire design. Thousand Oaks, CA:
17 Sage Publications 2005.
- 18
19 48. Collins D. Pretesting survey instruments: An overview of cognitive methods. *Qual Life Res*
20 2003;**12**:229–38. doi:[10.1023/A:1023254226592](https://doi.org/10.1023/A:1023254226592)
- 21
22 49. Van Someren M, Barnard Y, Sandberg J. The think-aloud method. London: Academic Press; 1994.
- 23
24 50. Harris PA, Taylor R, Thielke R, *et al*. Research electronic data capture (REDCap)--a metadata-
25 driven methodology and workflow process for providing translational research informatics support. *J*
26 *Biomed Inform* 2009;**42**:377–81. doi:[10.1016/j.jbi.2008.08.010](https://doi.org/10.1016/j.jbi.2008.08.010)
- 27
28 51. Van Alphen TC, Poulsen L, van Haren ELWG, *et al*. Danish and Dutch linguistic validation and
29 cultural adaptation of the WOUND-Q, a PROM for chronic wounds. *Eur J Plast Surg* 2019;1-10.
30 doi:[10.1007/s00238-019-01529-7](https://doi.org/10.1007/s00238-019-01529-7)
- 31
32 52. WHO (World Health Organization). The process of translation and adaptation of instruments.
33 Available at: http://www.who.int/substance_abuse/research_tools/translation/en/ (accessed May
34 2019)
- 35
36 53. Poulsen L, Rose M, Klassen A, *et al*. Danish translation and linguistic validation of the BODY-Q: a
37 description of the process. *Eur J Plast Surg* 2017;**40**:29–38. doi:[10.1007/s00238-016-1247-x](https://doi.org/10.1007/s00238-016-1247-x)
- 38
39 54. RUMM Lab. <http://www.rummlab.com.au/> (accessed 29 May 2019).
- 40
41 55. Smith EV. Detecting and evaluating the impact of multidimensionality using item fit statistics and
42 principal component analysis of residuals. *J Appl Meas* 2002;**3**:205–31.
- 43
44 56. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill, 1994.
- 45
46 57. Sample Size and Item Calibration or Person Measure Stability. Available at:
47 <http://www.rasch.org/rmt/rmt74m.htm> (accessed May 2019)
- 48
49 58. Terwee CB, Dekker FW, Wiersinga WM, *et al*. On assessing responsiveness of health-related
50 quality of life instruments: guidelines for instrument evaluation. *Qual Life Res* 2003;**12**:349–62. doi:
51 [10.1023/A:1023499322593](https://doi.org/10.1023/A:1023499322593)
- 52
53 59. Husted JA, Cook RJ, Farewell VT, *et al*. Methods for assessing responsiveness: a critical review and
54 recommendations. *J Clin Epidemiol* 2000;**53**:459–68. doi: [10.1016/S0895-4356\(99\)00206-1](https://doi.org/10.1016/S0895-4356(99)00206-1)
- 55
56 60. Brozek JL, Guyatt GH, Schünemann HJ. How a well-grounded minimal important difference can
57 enhance transparency of labelling claims and improve interpretation of a patient reported outcome
58 measure. *Health Qual Life Outcomes* 2006;**4**:69. doi:[10.1186/1477-7525-4-69](https://doi.org/10.1186/1477-7525-4-69)
- 59
60

Table 1: WOUND-Q interview guide**Wound**

1. How did your wound originate? **Probe:** any comorbid diabetes, obesity
2. Can you tell me about any wounds you've had in the past?
3. How was the healing process for you? **Probe:** hemostasis, inflammation, proliferation, and remodeling

Treatments

4. What treatment(s) have you had for your wound?
5. What was good/bad about the treatment(s)? **Probe:** side effects

Symptoms

6. Can you describe any symptoms you experience? **Probe:** e.g., pain, odor, exudate
7. Have symptoms changed over time? **Probe:** hemostasis, inflammation, proliferation, and remodeling
8. How bothersome are the symptoms?
9. How do you cope with the symptoms?

Recovery

10. How quickly did you recover?
11. What was the recovery process like? **Probe:** hemostasis, inflammation, proliferation, and re-modelling
12. Can you describe the early life impact? **Probe:** impact on physical, social, emotional, social life

Appearance

13. How would you describe the appearance of your wound? **Probe** for descriptive detail.
14. What do you like/dislike about the appearance of your wound?
15. How has your appearance changed? **Probe** hemostasis, inflammation, proliferation, and remodeling
16. Is there anything about the wound you wish looked different? **Probe** for descriptive detail.
17. Do/did you ever hide or cover your wound? How do you do this?

Physical Function

18. Does the wound create physical issues? **Probe:** e.g., mobility, activity limitations
19. How have these physical issues changed? **Probe** hemostasis, inflammation, proliferation, remodeling

Psychological Wellbeing

20. How does your wound affect how you feel? **Probe:** happy, sad, anxious, frustrated, self-conscious.
21. How does your wound affect how you feel about yourself? **Probe:** self-esteem; body image; confidence.
22. How have your emotions changed? **Probe** hemostasis, inflammation, proliferation, remodeling

Social Life


23. What has it been like for you at home? **Probe:** partner, family, children.
24. Has the wound affected your usual activities? **Probe:** work/education?
25. Do people ever comment on your wound? **Probe:** how did you react; how did you feel?
26. Are there things you would have liked to do but don't because of your wound?
27. Has anyone ever treated you differently because of your wound? **Probe:** friends, family, strangers.
28. How else does your wound affect your social life? **Probe:** with friends, meeting new people, dating.

Experience of Care

29. Who did you see at the hospital or clinic? **Probe:** doctor, nurse, receptionist, etc.
30. What are the people like who cared for you? **Probe:** friendly; made you feel comfortable; easy to talk to; listened to you; respectful; available.
31. What kind of verbal and written information did you receive? **Probe:** gave enough information; let you ask questions; answered your questions; information about recovery; treatment information
32. What things could the healthcare team do differently to improve the care you received?
33. What should the perfect wound healing center be like?

Other Questions


34. Is there anything I have not asked you that you think it is important for me to know?



Flow diagram illustrating the multiphase mixed methods approach to the development of the WOUND-Q. QUAN, quantitative study component; QUAL, qualitative study component. Image reproduced from Wong Riff et al [33]

78x108mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Translation and cultural adaption steps for the WOUND-Q. Image reproduced from Van Alphen et al [60]